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Summary 
 
Mycobacterium tuberculosis is the causative agent of one of the world's deadliest 
diseases, tuberculosis. The obligate pathogen parasites host macrophages by 
interfering with several cell-host pathways. One of the most peculiar feature of M. 
tuberculosis is the ability to arrest the phagosome maturation process. A new strategy 
of phagosome maturation arrest dependent on the M. tuberculosis zinc 
metallopeptidase Zmp1 has been recently described.  Zmp1 suppresses the activation 
of a multiprotein complex termed inflammasome, preventing the caspase-1 
processing of IL-1β and the subsequent phagosome maturation. Zmp1 is required for 
virulence of M. tuberculosis in mice. The emerging role of Zmp1 as virulence 
determinant was exploited for generating a vaccine based on the inactivation of 
zmp1. A BCG zmp1 deletion mutant showed an increased immunogenicity in mice 
compared to the wild-type. The key role of Zmp1 in mycobacterial pathogenicity and 
its application in vaccine made of utmost importance the functional characterization 
of the enzyme. The aims of this study were 1) to provide insights into the structure 
and biochemical properties of Zmp1 and 2) to generate recombinant live vaccine 
candidates against tuberculosis based on zmp1 inactivation. 
First, the crystal structure of the M. tuberculosis Zmp1 was resolved at 2.6 Å by co-
crystallization in complex with the competitive inhibitor phosphoramidon. The 
Zmp1 structure revealed significant similarities with the human neprilysin and 
endothelin converting-enzyme 1, identifying Zmp1 as the first prokaryotic member 
of the M13 endopeptidases. The Zmp1 substrate specificity was investigated by 
employing a microarray based peptide library. Several bioactive peptides were 
identified as in vitro substrates, including the neuropeptides bradykinin, neurotensin, 
neuropeptide FF, substance P and apelin. We determined the specific cleavage site 
within neuropeptides by mass spectrometry, concluding that Zmp1 shares structure, 
substrate specificity and substrate cleavage pattern with the human neprilysin and 
endothelin converting enzyme-1. Within the M13 endopeptidase family, Zmp1 
represents the first prokaryotic member which is structurally and biochemically 
characterized.  
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The second part of this work focuses on the generation of zmp1-based vaccine strains 
with appropriate characteristics for further application in humans, such as sensitivity 
towards first and second line tuberculosis drugs. BCG zmp1::aph and BCG ureC::hly 
are two promising vaccine candidates. The first is in preclinical studies and the 
second entered the clinical trials. However, both carry antibiotic markers and 
therefore their use is limited. To overcome these limitations, BCG ∆zmp1 and BCG 
ureC::hly were generated in the substrain Denmark, without antibiotic resistance 
markers. Moreover, the combinatorial vaccine strain BCG Denmark ∆zmp1 ureC::hly 
was generated as the combination of the properties of the single mutants might 
further improve the protective efficacy and safety profile of the vaccine. 
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Zusammenfassung 
 
Mycobacterium tuberculosis ist der Erreger der Tuberkulose, eine der tödlichsten 
Infektionskrankheiten weltweit. Der Krankheitserreger parasitiert in 
Wirtsmakrophagen indem er zelluläre Abwehrmechanismen inhibiert. Eine der 
bemerkenswertesten Eigenschaften von M. tuberculosis ist dessen Fähigkeit die 
Phagosomenreifung zu inhibieren. Ein neuartiger Mechanismus der Inhibition der 
Phagosomenreifung, basierend auf der M. tuberculosis Zink-Metallopeptidase Zmp1, 
wurde erst kürzlich beschrieben. Zmp1 unterdrückt die Aktivierung eines 
Multiproteinkomplexes, Inflammasom genannt, und damit die Caspase-1-abhängige 
pro-IL-1β Prozessierung. Matures IL-1β stimuliert die Reifung von Phagosomen. 
Eine M. tuberculosis zmp1 Deletionsmutante ist attenuiert. Aufgrund der zentralen 
Bedeutung von Zmp1 wurde eine Mycobacterium bovis BCG zmp1 Mutante als 
potentieller Tuberkuloseimpfstoff  generiert. Diese BCG zmp1 Deletionsmutante wies 
im Vergleich zu BCG eine erhöhte Immunogenität in Mäusen auf. Die Schlüsselrolle 
von Zmp1 in der Pathogenität von Mykobakterien sowie die Eigenschaften eines 
zmp1-basierten Impfstammes lassen eine funktionelle Charakterisierung dieses 
Enzyms äusserst interessant erscheinen. Ziele dieser Studien waren 1) die 
strukturelle und biochemische Charakterisierung von Zmp1 und 2) die Generierung 
verbesserter rekombinanter zmp1-basierter Lebendimpfstoffe gegen die Tuberkulose.  
Zunächst wurde die Kristallstruktur von M. tuberculosis Zmp1 als Komplex mit dem 
kompetitiven Inhibitor Phosphoramidon mit einer Auflösung von 2.6 Å ermittelt. Die 
Struktur von Zmp1 zeigte dabei signifikante Ähnlichkeit mit humanem Neprilysin 
und Endothelin-converting enzyme-1 (ECE-1). Zmp1 ist der erste Vertreter der M13 
Endopeptidasen, dessen Struktur bestimmt wurde. Die Substratspezifität von Zmp1 
wurde mit Hilfe einer Micro-Peptidbank bestimmt. Mehrere bioaktive Peptide 
konnten dabei als in vitro Substrate identifiziert werden, darunter die Neuropeptide 
Bradykinin, Neurotensin, Neuropeptid FF, Substance P und Apelin. Die Schnittstellen 
innerhalb der Neuropeptide wurden mittels Massenspektrometrie ermittelt und 
ähnelten denjenigen von Neprilysin und ECE-1. Somit ähnelt Zmp1 sowohl 
bezüglich der Struktur als auch bezüglich der Substratspezifität und 
Substratschnittstellen den humanen Peptidasen Neprilysin und ECE-1. Innerhalb der 
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M13 Endopeptidase Familie repräsentiert M. tuberculosis Zmp1 damit den ersten  
prokaryontischen Vertreter, welcher strukturell und biochemisch charakterisiert 
wurde. 
Der zweite Teil dieser Arbeit fokussiert auf der Weiterentwicklung von zmp1-
basierten Impfstämmen. Für die Anwendung am Menschen ist insbesondere deren 
Sensitivität gegenüber First- und Secondline Tuberkulostatika wichtig. BCG zmp1::aph 
und BCG ureC::hly sind zwei vielversprechende Impfstoffkandidaten. Ersterer 
befindet sich in vor-klinischen Studien, während sich der Zweite bereits in klinischen 
Studien befindet. Beide Stämme tragen jedoch Antibiotikaresistenzmarker, was ihre 
Verwendung einschränkt. Um diese Limitierung zu umgehen wurden in dem BCG 
Substamm Denmark die Allele ∆zmp1 und ureC::hly ohne jedweden 
Antibiotikaresistenzmarker eingebracht. Darüber hinaus wurde ein 
kombinatorischer Stamm, BCG Denmark ∆zmp1 ureC::hly generiert. Durch die 
Kombination der Eigenschaften der Parentalstämme dürfte eine weitere 
Verbesserung der Protektivität und Sicherheit erreicht werden.  
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INTRODUCTION 
 
1. Tuberculosis. History, epidemiology and therapy 
 
 
In the first papers concerning the aetiology of tuberculosis I have already indicated the 
dangers arising from the spread of the bacilli-containing excretions of consumptives, and have 
urged moreover that prophylactic measures should be taken against the contagious disease. 
But my words have been unheeded. It was still too early, and because of this they still could 
not meet with full understanding. It shared the fate of so many similar cases in medicine, 
where a long time has also been necessary before old prejudices were overcome and the new 
facts were acknowledged to be correct by the physicians.  
 
Robert Koch 
“The current state of the struggle against tuberculosis”, Nobel Lecture (12 Dec 1905) 
 
 
One century after Robert Koch’s Nobel lecture, tuberculosis (TB) still remains a major 
global health threat. Tuberculosis has plagued mankind worldwide for thousands of 
years.  More than 2000 years ago in ancient Greece, Hippocrates called the most 
common cause of illness in his time "phthisis" (Hippocrates, Aphorisms). Over the 
centuries since Hippocrates, tuberculosis has been known as a major scourge of the 
human species. The disease was named the Great White Plague in the 17th century in 
Europe, where tuberculosis was epidemic and the principal cause of death for two-
hundred years (Dubos, 1952, The White Plague: Tuberculosis, Man, and Society). 
Malnutrition, high population density as well as poor sanitary conditions in the 
European and North American cities created a fruitful field for spreading of the 
disease. The historic menace of the "White Plague" continued for many centuries 
because of poor understanding of the disease and unappropriate medical tools to 
fight it. Tuberculosis still remains a disease of poverty strongly interconnected with 
undernutrition and overcrowding (Lawn and Zumla, 2011).  Most cases occur in Asia 
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and Africa, with smaller proportions of cases in European region, in the eastern 
Mediterrean and the Americas.  The devastating effect of HIV on susceptibility to 
tuberculosis has dramatically increased the tuberculosis incidence rate in many high 
HIV prevalence countries in sub-Saharan Africa (about four of every five cases) 
(WHO, 2010). In fact, the risk of developing tuberculosis for HIV infected people was 
evaluated to be more than 20-times greater than that of non-infected individuals 
(WHO, 2009). 
The incidence of TB in 2010 is worrisome; 8.8 million new cases have been estimated, 
and 1.4 million people died from TB. Overall, one-third of the world's population is 
currently infected with the aetiologic agent Mycobacterium tuberculosis (Mtb), but only 
5-10% of infected people (who are not infected with HIV) will develop active disease 
in their lifetime (WHO, 2010). Indeed, most immuno-competent individuals infected 
with M .tuberculosis either eliminate the pathogen or co-exist with it in a latent state. 
Latent tuberculosis is a clinical disorder in infected individuals in whom the host 
immune system keeps under control the bacterial multiplication such that the 
infection remains asymptomatic. In those individuals, the infection can reactivate 
years later or even decades, resulting in active and contagious tuberculosis. The risk 
of reactivation is increased in immuno-compromised persons, such as HIV infected 
individuals (Algood et al., 2003). 
 M. tuberculosis is an obligate pathogen, able to infect several animal species, but 
human beings are its principal host. As aerobic bacillus, it grows preferentially in 
tissue with high oxygen content, such as lungs. The complex and not fully 
understood strategy of survival of M. tuberculosis in the host represents its key of 
success. M. tuberculosis hides into macrophages, targeting therefore the primary host 
defence against microbial invasion. The successful parasitization of macrophages 
results in the multiplication of the bacteria while the immune system is silenced. The 
intracellular survival is guaranteed by multiple factors. The thick mycobacterial cell 
wall represents a physical barrier to mechanical and chemical stress, such as the 
hydrolytic enzymes within the macrophages. M. tuberculosis virulence factors 
comprise a real arsenal for the defence against the host attacks, such as the 
mycobacterial enzymes that detoxify reactive radicals. The most striking feature of 
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pathogenic mycobacteria is the ability to block the normal process of phagosome 
maturation, resulting in the growth in a non-acidified intracellular compartment. 
The WHO-recommended chemotherapeutic regimen against tuberculosis consists of 
four out of five first line drugs (rifampicin, isoniazid, pyrazinamide, ethambutol and 
streptomycin) for initial two months, and a following treatment with rifampicin and 
isoniazid for the next four months. This long-lasting therapy is designed to kill the 
replicating bacteria in the first phase with usage of multiple drugs and the next four 
months treatment is supposed to eradicate the remaining non-replicating bacteria. 
Nevertheless, many factors thwart the success of the therapy. The granuloma, 
because of its highly differentiated internal structure, offers multiple micro-
enviroments for Mtb. Hence, it is populated by bacterial sub-populations in different 
growth phases and therefore with diverse metabolic activities. The drugs currently 
used preferentially target replicating organisms, so that the nonreplicative sub-
populations are protected by innate resistance mechanisms. The innate resistance of 
nonreplicating Mtb contributes substantially to the protracted chemotherapeutic 
treatment (Russell et al., 2010).   
The duration, high cost and drug-related adverse effects of the therapy are often the 
reason for patient noncompliance, which, worsened by inadequate health-care 
oversight, results in increasing proliferation of drug-resistant strains. MDR-TB 
(multidrug-resistant tuberculosis) is a specific form of TB caused by resistant Mtb to 
at least isoniazid and rifampicin, the two most powerful anti-TB drugs. MDR-TB 
strains further resistant to fluoroquinolone and an injectable second-line drug 
(kanamycin, amikacin and/or capreomycin) are called XDR-TB (extensively drug-
resistant tuberculosis). While drug-susceptible TB can be cured within six months, 
MDR-TB requires extensive chemotherapy (with drugs which are more expensive 
and have severe side effects) for up to two years. Instead, for XDR-TB cases treatment 
options are seriously limited. It was estimated that 440 000 people developed MDR-
TB worldwide in 2008 and that a third of them died. Almost 50% of MDR-TB cases 
worldwide are estimated to occur in China and India (WHO's Multidrug and 
Extensively Drug-Resistant Tuberculosis: 2010 Global Report on Surveillance and 
Response). The growing global burden of multidrug-resistant tuberculosis urges the 
need for development of fast-acting medications and new effective vaccines. 
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2. Microbiology of M. tuberculosis 
Mycobacterium is a genus of Actinobacteria which includes more than 130 species. 
The genus encompasses a number of medically important species, including the 
aetiological agent of tuberculosis M. tuberculosis and the causative agent of leprosy 
M. leprae.  Species relevant for their applications are M. bovis BCG, the vaccine strain 
used against tuberculosis, and M. smegmatis, a non-pathogenic mycobacterial model 
organism. Mycobacteria are straight or slightly curved nonmotile rods 
(approximately 0.2–0.6 µm wide by 1.0–10 µm long), nonsporeformers. Two 
remarkable features define mycobacteria. First, they have a thick cell wall enriched in 
uncommonly long-chain fatty acids with 60 to 90 carbons, known as “mycolic acids”, 
attached to the cell wall through the polysaccharide arabinogalactan. The mycolic 
acids layer give the colonies their characteristic waxy appearance and the cells a 
tendency to clump and resist dispersion. The waxy nature of the cell envelope makes 
the bacteria weakly stainable with Gram’s method dyes, though the bacteria are 
categorized as Gram positive. Mycobacterial mycolic acids form, however, strong 
complexes with some chemicals, as carbol fuchsin dye, that leave them resistant to 
decolorization with acid alcohol. For that reason mycobacteria are defined acid-
alcohol fast. In addition, the lipid coat confers to mycobacteria a strong resistance to 
many antiseptic solutions and antibiotics. Second, mycobacteria grow relatively 
slowly with generation times ranging from 2 hours for M. smegmatis (classified 
therefore as fast growing mycobacteria) to 12 days for M. leprae (slow growing 
mycobacteria). M. tuberculosis belongs to the group of slow growing mycobacteria, 
with a generation time of 20 to 24 hours. The genus Mycobacterium shares the 
production of mycolic acids and an unusually high genomic DNA GC content (62–
70%) with two closely related genera, Nocardia and Corynebacterium, within the order 
Actinomycetales.  The complete genome sequence of the M. tuberculosis laboratory 
strain H37Rv was elucidated in 1998 (Cole et al., 1998).  The genome sequence 
comprises 4.4 Mbp, and contains 3,924 open reading frames. The genome is rich in 
repetitive DNA sequences, particularly insertion sequences in intergenic or non-
coding regions, often near tRNA genes. The mycobacterial genome is composed by 
genes needed for adaptation of the bacterium to a range of environmental conditions, 
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from growth in a rich broth to survival in host macrophages. Moreover, some 
components of several anaerobic phosphorylative electron transport chains were 
found, conferring to the bacterium the ability to survive also in anaerobic 
environment, such as the core of granuloma. The genome also possesses an 
extraordinary large number of genes involved in lipid metabolism: 250 distinct 
enzymes involved in complex fatty acid biosynthesis and degradation.  
The architecture of the mycobacterial cell envelope is peculiar and rather complex. It 
includes the plasma membrane, the periplasmic space, the mycomembrane and the 
capsular layer. Such unique structure is placed in between the Gram positive and 
Gram negative cell envelope structures. The cytoplasmic membrane is encapsulated 
by a layer of peptidoglycan, which peculiarly contains N-glycolylmuramic acid 
instead of N-acetylmuramic acid (Brennan and Nikaido, 1995). The peptidoglycan is 
connected through a phosphodiester link to a second component of the periplasmic 
layer, the arabinogalactan. The mycolic acids are bound to arabinogalactan by ester 
bonds, forming the mycomembrane. By hydrophobic interactions, the mycolic acids 
interact with free glycopeptidolipids and free glycolipids, creating an outer 
membrane-like structure, which is followed by a capsular layer. A major component 
associated to the mycobacterial cell wall is the immunogenic lipoarabinomannan 
(LAM), which is attached to the cytoplasmic membrane by a phosphatidylinositol 
anchor. M. tuberculosis LAM are mannose capped (ManLAM), whereas 
nonpathogenic species lack the glyco-modification (Vercellone et al., 1998). The 
mannose-capped lipoarabinomannan have been shown to be the key effector in the 
process of phagosome maturation arrest (Fratti et al., 2001; Fratti et al., 2003). 
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Fig.1 Schematic representation of the architecture of the mycobacterial cell wall (Abdallah et al., 2007). 
 
3. Pathogenesis of tuberculosis 
Infection with M. tuberculosis follows a well-established pattern of events (Fig.2). The 
infectious bacilli are inhaled as droplet nuclei from the atmosphere. These droplets 
remain airborne for several hours, and the minimum infection dose ranges from a 
single bacterium upward (Russell et al., 2010). In the lung the bacteria are 
phagocytosed by alveolar macrophages, inducing a localized inflammatory response 
that leads to recruitment of mononuclear cells from neighboring blood vessels, 
providing fresh host cells to infect. These cells are the starting point for building the 
granuloma, which is the pathologic feature of tuberculosis. In the early stage, 
granuloma is an amorphous mass composed of macrophages, neutrophils and 
monocytes; macrophages, however, undergo to differentiation into multinucleated 
giant cells, epithelioid macrophages and foamy macrophages. When lymphocytes 
arrive and the acquired immune response is initiated, the granuloma develops into 
an organized, and stratified structure, surrounded by a fibrous cuff which clearly 
confines the mass. The active bacterial replication lasts for two to three weeks; 
afterwards, the appearance of Mtb-specific lymphocytes symbolizes the end of this 
phase and the beginning of the “containment” state. During that phase, the 
granuloma is extensively vascularized, the cells are continuously recruited and the 
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bacterial count is relatively stable. The disease progression is then associated with 
decreasing vascularization and thickening of the fibrous sheath, along with the 
increase of number of foamy macrophages mainly responsible for the typical caseous 
areas in the center of the granuloma. The late stage of the infection is characterized 
by hypoxic condition inside the granuloma, which induces a state of non replication 
of bacteria. Active granulomas exhibit extensive pathology, and their rupture is 
responsible for spilling of thousand of viable, infectious bacilli into the airways. At 
this step, spreading of the infection occurs by coughing. Containment of rupture 
usually fails when the host immune system is compromised, and this may 
correspond to malnutrition, aging or co-infection with HIV. In general, any condition 
which affects the number or function of CD4 T cells represents a high risk for 
activation of the disease (Russell, 2007; Russell et al., 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.2 The progression of M. tuberculosis pathology  (Russell et al., 2010). 
 
Granuloma play a contradictory role in tuberculosis pathology. Granuloma 
formation functions as a host defense mechanism, which contains the infection site. 
Indeed, macrophages are able to kill mycobacteria, and control their growth. 
Although M. tuberculosis inhibits apoptosis and immune responses, it is still capable 
of basal CD4 T cells stimulation, and in minor extent CD8 T cells stimulation 
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(Kaufmann, 2004). In fact, in HIV infected individuals, granulomas are absent, 
resulting in an uncontrolled Mtb dissemination (Lawn et al., 2002). On the other 
hand, granuloma confer many advantages to M. tuberculosis. Pathogenic 
mycobacteria promote cellular recruitment to the granuloma, and newly recruited 
macrophages provide their primary growth niche (Davis and Ramakrishnan, 2009). 
Inside the granuloma, mycobacteria might evade massive and effective innate 
immune mechanisms thereby delaying the start of an adaptative immune response. 
Moreover, such dense structure shields themself from therapeutic concentration of 
anti-tuberculosis drugs, potentially promoting the emergence of drug-resistant 
strains (Lawn and Zumla, 2011). From this point of view, granuloma formation 
might be seen as a part of the mycobacteria directed virulence program.  
Tuberculosis affects predominantly the lungs, and the most common clinical 
manifestation of tuberculosis is pulmonary disease. Nevertheless, about 15% of the 
patients with active tuberculosis, develop miliary or extra-pulmonary TB. The 
bacteria, in fact, can disseminate to diverse parts of the body through invasion of 
blood stream. The interested organs are lymph nodes, liver, pleura, spleen, bones 
and joints. The most serious clinical manifestation of tuberculosis is the involvement 
of the central nervous system, resulting in tuberculous meningitis, which is fatal in 
almost all cases without a prompt chemotherapy (Frieden et al., 2003). Disseminated 
tuberculosis is characterized by involvement of many organs simultaneously and it 
results from primary progressive disease or reactivation of latent infection. General 
symptoms caused by TB are persistent cough, fever, weight loss, night sweat, 
shortness of breath and chest pain. However, in the early stage of disease,  mostly 
because of macrophages containment work, symptoms might be absent (Ducati et al., 
2006).  
 
4. The life of M. tuberculosis inside the phagosome 
The successful parasitization of the macrophage by M. tuberculosis involves the 
manipulation of the host signalling pathways, causing the impairment of its natural 
main function: innate and adaptative immune response effector. Pathogenic 
mycobacteria, unlike non-pathogenic species, are capable of inhibition of several host 
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processes in order to guarantee the survival and multiplication inside the host. Four 
main processes are affected by Mtb: phagosome maturation, antigen presentation, 
apoptosis and stimulation of bactericidal responses (Fig.3A). Pathogenic 
mycobacteria, in contrast to non-pathogenic mycobacteria, disrupt the mitogen-
activated protein kinase (MAPK) pathway inhibiting the activation of p38 and 
ERK1/2. As consequence, the production of pro-inflammatory cytokines and 
chemokines, which are needed to induce a cellular innate immune response, is 
impaired (Koul et al., 2004). The corruption of the host apoptotic pathway is a 
strategy delivered by Mtb to avoid cross-priming, which leads to CD8 T cell 
stimulation. The mycobacterial virulence factor Man-LAM promotes the 
phosphorylation of the apoptotic protein Bad through the protein kinase B Akt, 
leading to its dissociation from the anti-apoptotic protein Bcl-2, and its consequent 
anti-apoptotic effects in infected cells (Maiti et al., 2001). Mtb also limits macrophage 
apoptosis by inducing the production of the immuno-suppressive cytokine 
interleukin-10 (IL-10), which in turn blocks the synthesis of the potent stimulator of 
apoptosis, tumour-necrosis factor-α (TNF-α), in infected macrophages (Balcewicz-
Sablinska et al., 1998).  
The most peculiar feature of M. tuberculosis is the ability to arrest the phagosome 
maturation process. Phagosome maturation involves a sequence of fusion events 
with various vesicles, by which the nascent phagosome maturates into a specialized 
acidic compartment with microbicidal properties, the phagolysosome. After bacterial 
ingestion, the phagosome acquires markers, such as the small GTPase Rab5, that 
recruits phosphatidylinositol-3-kinase (PI3K). This kinase produces a molecule, 
phosphatidylinositol-3-phosphate (PI3P), necessary for recruitment of early 
endosomal antigen (EEA1). EEA1 is the key effector to allow the maturation process 
through the fusion of phagosomes with late endosomes. It serves as an organelle 
tethering molecule by bridging membranes destined for fusion (Vergne et al., 2004a). 
During maturation, the phagosome loses Rab5 and acquires another GTPase, Rab7, 
and following fusions with lysosomal vesicles equip the compartment with the 
lysosome-associated membrane protein 1 (LAMP1), acid hydrolysases, such as 
cathepsin D, and the vacuolar proton-ATPase which acidifies the phagolysosome. 
The whole process is Ca2+ sensitive. In fact, in the early steps, an increased 
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intracellular concentration of Ca2+ activates calmodulin and calmodulin-dependent 
protein kinase CaMKII, which are responsible for recruiting PI3K. M. tuberculosis 
evolved a mechanism to arrest phagosome maturation playing on its critical point, 
Ca2+ concentration. The pathogen inhibits cytosolic Ca2+ rise through the lipid 
effector Man-LAM, which is able to block ionophore-induced increases in 
Ca2+concentration in macrophages (Rojas et al., 2000). As Man-LAM inhibits the 
increase in cytosolic Ca2+ concentration, it impairs the Ca2+ /calmodulin recruitment 
of PI3K to the phagosomes and thereby further obstructs phagosomal maturation. 
Mycobacterial phagosomes therefore do not recruit EEA1, which, as mentioned 
above, is essential for the fusion of the phagosome with lysosomal vesicles. The 
incomplete maturation of the M. tuberculosis vacuole confers unique characteristics to 
this environment: absence of mature hydrolases, limited acidification to pH 6.4 
(phagolysosome pH is usually 4.8) and active trafficking with early endosomes for 
acquisition of nutrients (Russell, 2001; Vergne et al., 2004a) (Fig.3B). It is clear that 
pathogenic mycobacteria arrest phagosome maturation. However, the molecular 
details have yet to be elucidated. So far, several mechanisms have been suggested, 
taking to the conclusion that multiple mycobacterial effectors are involved in the 
corruption of phagosome trafficking (Pethe et al., 2004). Surface lipids such as Man-
LAM and cord factor (a mycobacterial trehalose dimycolate) have been shown to 
inhibit Ca2+ -induced vesicular fusion (Fratti et al., 2003; Indrigo et al., 2003; Vergne et 
al., 2003), and the phosphatidylinositol mannoside (PIM) stimulates fusion between 
phagosome and early endosomes, that are a source of nutrients (Vergne et al., 2004b). 
Moreover, some mycobacterial proteins revealed a key role in this process, as the 
bacterial serine/threonine kinase PknG (Walburger et al., 2004), the mycobacterial 
urease UreC, which produces ammonia that blocks vacuole acidification (Reyrat et 
al., 1996), the acid phosphatase SapM (Vergne et al., 2005) and the zinc 
metallopeptidase Zmp1 (Master et al., 2008). It is well established that macrophage 
activation with IFN-γ prior to infection with M. tuberculosis enables the host cell to 
overcome the blockage in phagosome maturation and deliver the bacterium to an 
acidic, hydrolytically competent phagolysosome (Schaible et al., 1998). The 
mechanism behind was suggested to rely on a small GTP-binding protein, LRG-47, 
which is selectively upregulated upon IFN-γ activation, and it facilitates the delivery 
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of vacuolar H+ ATPase subunits to the phagosome, supporting the phagosome 
acidification (MacMicking et al., 2003).  
 
 
 
Fig.3 (A) Representation of the host signalling pathways regulated by pathogenic and non-pathogenic 
mycobacteria (Koul et al., 2004). (B) The vacuole containing M. tuberculosis appears as a not hostile 
environment with respect to pH, hydrolytic activity and nutrient supply. Phagosomes containing IgG-
coated beads acidify rapidly to pH lower than 5 because of fusion with lysosomes  (Russell, 2007). 
 
5. Zinc metallopeptidases. An overview from mammals to 
bacteria 
Zinc metallopeptidases have physiological roles in the life cycle of the organisms, 
and they are essential factors for homeostatic control in both eukaryotes and 
prokaryotes. Several opportunistic pathogens use zinc metallopeptidases as toxic 
factors to the host. These toxic peptidases show a variety of pathological actions, 
because of their versatile proteolytic activity towards many kinds of host proteins, 
such as plasma proteins and structural component of the tissues. With the exception 
of a few cases, the precise role of zinc metalloproteases in bacterial pathogenesis has 
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not yet been elucidated. The striking virulence of some pathogens relies solely on 
zinc metallopeptidase. Glaring examples are the metallopeptidase from Vibrio 
vulnificus which, enhancing the vascular permeability by stimulating the production 
of inflammatory mediators histamine and bradykinin, causes serious septicemia and 
edematous skin lesions in humans (Miyoshi et al., 1994); Vibrio cholera secretes a 
metallopeptidase which activates cholera toxin, a prototype A-B subunit toxin, 
through digestion of the A subunit (Booth et al., 1984), and a metallopeptidase from 
the Vibrio cholera serovar  O1, the causative agent of pandemic cholera, accelerates the 
bacterial attachment to intestinal epithelial cells through digestion of the small 
intestine mucosa, thereby destroying the protective barrier and providing nutrients 
to the bacterial population (Ichinose et al., 1994). Beside the impact of zinc 
metallopeptidases in enteropathogenicity and vascular permeability, necrotic tissue 
damage represents the most classic pathogenic mechanism of bacterial peptidase. 
Pseudolysin, an extracellullar elastase of Pseudomonas aeruginosa, destroys tissue and 
damages cell functions, has hemorrhagic activity, muscle damaging effects, and 
causes chronic ulcers by degradation of human wound fluids and human skin 
proteins (Adekoya and Sylte, 2009). Among the bacterial metallopeptidases with the 
most devastating effect belongs the lethal factor of Bacillus anthracis. The peptidase is 
a part of the three component anthrax toxin, and it works inactivating key signaling 
molecules, such as mitogen-activated protein kinase kinases (MAPKK), to ultimately 
cause cell death (Panchal et al., 2004).  
Zinc metallopeptidases are classified into four groups, namely DD-carboxypeptidase, 
carboxypeptidases, zincins and inverzincin (Fig.4). The ‘zincins superfamily’ is 
characterized by the zinc-binding motif HEXXH. This superfamily is subdivided in 
seven families, and the most representative bacterial ones are three: thermolysin 
having Bacillus thermoproteolytics metallopeptidase as prototype enzyme, serralysin 
with the metallopeptidase from Serratia marcescens as prototype, and neurotoxin 
family represented by Clostridium botulinum and Clostridium tetani metalloenzymes 
(Miyoshi and Shinoda, 2000). In the HEXXH motif, the two histidines are zinc ligands 
and the glutamic acid has catalytic function as it polarizes the water molecule that 
attacks the peptide bond of the substrate (Fig.5). The zinc atom is tetrahedrally-
coordinated by a third ligand which is usually a residue of glutamic acid, and a 
 27
fourth ligand that is a molecule of water that becomes activated and mediates the 
nucleophilic attack on the scissile peptide bond (MEROPS). 
           
 
                                  
Fig.4  Zinc metallopeptidases families classified on the base of the sequence around the zinc-binding 
residues. Letters in italic represent the identified zinc ligands; underlined red letters are putative zinc 
ligands; X stands for any amino acid.  Residues in the line a correspond to the first and second zinc 
ligands; residues in the line b to the third ligand and those in the line c to the putative fifth ligand 
(Miyoshi and Shinoda, 2000). 
 
 
 
Fig.5  Scheme representing the catalytic mechanism of zinc metallopeptidases (Hernick and Fierke, 
2005). 
 
The endopeptidase-24.11 family belongs to the ‘zincins superfamily’, and it deserves 
a closer look because of the physiological importance of its members. The family was 
named in MEROPS database as M13 metallopeptidase family, and the prototype is 
neprilysin (NEP). The neprilysin family is a large group of medically and 
developmentally important enzymes. Indeed, the members of this family are 
M13 family 
a 
 
 
 
b 
 
 
 
 
c 
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involved in the metabolism of a number of regulatory peptides of the mammalian 
nervous, cardiovascular, immune and inflammatory system. They target small 
peptides (not longer than 40 residues) such as tachykinins, enkephalins, natriuretic 
and chemotactic peptides. The majority of M13 peptidases described so far exhibits a 
strong preference for cleaving the amino terminal bond of hydrophobic residues 
(Bland et al., 2008). The prototype neprilysin is the best characterized member, 
biochemically and structurally investigated. Neprilysin is widely distributed in 
mammalian tissues and has important role in inactivating signaling peptides. At 
nervous system level, it degrades endogenously released enkephalins, thereby 
regulating opioid peptide action, and other neuropeptides of the tachykinin family 
such as substance P (Turner et al., 2001). Neprilysin modulates blood pressure by 
physiological degradation of hormone peptides such as cardiac hormone natriuretic 
peptide (ANP), bradykinin and endothelin (Oefner et al., 2000). NEP takes part also 
in various cancers, due to its ability to turn off mitogenic peptide signals, mediated 
by bombesin-like peptides or endothelins (Turner et al., 2001). NEP is potentially an 
important drug target, and there is a great interest in developing novel inhibitors of 
NEP for application in clinical treatment as analgesics or anti-hypertensive agents. 
Phosphoramidon is one of the most selective and potent inhibitor of M13 peptidases 
in general and NEP in particular. Recent reports showing that brain NEP can 
degrade the neurotoxic β-amyloid peptide involved in Alzheimer’s disease, raises 
new concerns about the chronic blockade of NEP activity, at least in CNS, by using a 
potent inhibitor as phosphoramidon. In fact, the NEP inhibition results in 
pathological accumulation of amyloid in vivo (Iwata et al., 2000). Thus, it appears that 
a critical balance of NEP is needed to guarantee homeostasis of peptide signaling 
events in order to avoid pathological states.  
Other members of the M13 family are endothelin-converting enzymes (ECE-1 and 
ECE-2), the erythrocyte surface antigen KELL and the phosphate-regulating neutral 
endopeptidase PHEX. ECE-1 and NEP were discovered on the basis of their 
activities, whereas all the other members of the family were identified by their 
sequence similarity. The overall homology between NEP and ECE-1, ECE-2, KELL 
and PHEX is 35 %, 30 %, 31 %, and 25 %, respectively, but increases to 51 %, 44 %, 43 
%, and 39% if only the 250 C-terminal residues are considered (Oefner et al., 2000). 
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The high degree of similarity suggests that these peptidases have common origin and 
a similar fold. Their enzymatic activities were investigated over the past years, but so 
far only the crystal structures of NEP and ECE-1 both complexed with 
phosphoramidon have been resolved (Oefner et al., 2000; Schulz et al., 2009). The M13 
peptidases are type II integral membrane proteins, and they all consist of a short N-
terminal cytoplasmatic domain, followed by a single transmembrane helix, and a 
large C-terminal extracellular domain that contains the active site. Another common 
structural feature includes the ten conserved cysteine residues in the extracellular 
domain, four of which are clustered close to the transmembrane anchor. They form 
intrachain disulfide bridges which confer stability to both  structure and function 
(Tam et al., 1985). The structure of the extracellular domain of NEP is characterized 
by two domains that enclose a large central cavity containing the active site. The 
larger N-terminal domain, which shows high similarity with thermolysin, includes 
the critical residues for zinc coordination and catalysis. The C-terminal domain 
restricts the active site access and thus functions as molecular sieve (Oefner et al., 
2000). The two-domain structure of NEP, with a peculiar substrate size-restricting 
region, reveals its nature as oligopeptidase (the majority of the natural substrates of 
NEP are restricted to about 3000 Da), whereas thermolysin, missing that domain, 
cleaves protein substrates (Fig.6).  
The bacterial homologues of the M13 family have not yet been characterized. In 
mycobacteria little is known about metallopeptidases and their potential role in 
virulence. TubercuList and MEROPS databases report only six annotated 
metallopeptidases in M. tuberculosis, on the basis of the common HEXXH motif. 
These are the zinc metallopeptidase Zmp1 (Rv0198c), the aminopeptidase N 
(Rv2467), the membrane-bound protease FtsH (Rv3610c), the protease heat shock 
protein X (Rv0563), the hypothetical protein encoded by the ORF Rv1977 and the 
membrane-bound zinc metallopeptidase Rip (Rv2869c). Both zinc metallopeptidases 
Zmp1 and Rip have been reported as important virulence determinants. Rip, a non-
essential intramembrane cleaving protease, regulates cell envelope lipid composition 
in M. tuberculosis by cleaving three transmembrane anti-sigma factors which control 
multiple downstream pathways involved in lipid biosynthesis (Sklar et al., 2010). Rip 
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is required for both M. tuberculosis growth and persistence in mice (Makinoshima 
and Glickman, 2005).  
 
                                   
 
Fig.6  Ribbon plot of soluble NEP depicting the volume of the active site cavity. The large N-terminal 
catalytic domain is colored in violet and the smaller C-terminal domain in blue. The three inter-
domain linker fragments are represented in cyan. The inhibitor phosphoramidon is nestled in the 
interior of the cavity of the large catalytic domain  (Oefner et al., 2000). 
 
Recently, a new strategy of mycobacterial phagosome maturation arrest relying on 
the M. tuberculosis zinc metallopeptidase Zmp1 has been described (Master et al., 
2008). The evidences of the involvement of Zmp1 in virulence and survival in 
macrophages were provided by using mycobacteria deficient in Zmp1. In vivo 
experiments showed that Zmp1 is necessary for full virulence in mice, since Mtb 
knockout mutant displayed reduced survival in mice. Moreover, phagosomes 
harboring Zmp1 mutant mycobacteria undergo enhanced maturation into 
phagolysosomes, suggesting that Zmp1 is required to maintain mycobacterial 
phagosome maturation arrest. The ability of mycobacteria to block phagosome 
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maturation relies on the Zmp1-dependent suppression of inflammasome activation. 
By the Zmp1-dependent inhibition of caspase-1 activation, mycobacteria prevent IL-
1β production and subsequently phagosome maturation. The exact mechanism of 
interaction between Zmp1 and the inflammasome is still unknown. Undoubtedly, 
Zmp1 plays a key role in M. tuberculosis pathogenicity, representing a promising 
target for tuberculosis drug intervention, and a molecular tool to dissect the unique 
properties of intracellular pathogens to parasitize host cells.  
 
6. Immune response to tuberculosis  
Control of M. tuberculosis is mainly the result of productive teamwork between 
macrophages and T-cells. T lymphocytes are central to the control of M. tuberculosis 
infection (Fig.7). The pathogen resides in the phagosome of macrophages, where 
mycobacterial peptides have access to the major histocompatibility complex class II 
(MHCII) molecules, that are shuttled to the cell surface and stimulate CD4 T cells. 
MHCI-restricted CD8 T cells are also stimulated by mycobacterial peptides, although 
the underlying mechanisms remain to be understood. It is thought that the major 
pathway responsible for stimulation of MHCI restricted T cell is the cross-priming 
(Kaufmann, 2004). M. tuberculosis induces apoptosis in infected macrophages and this 
results in the formation of apoptotic vesicles carrying mycobacterial peptides. These 
vesicles are taken up by dendridic cells (DC) and peptides are presented by MHCI 
molecules. Another hypothesis, which still remains controversial though supported 
by solid evidences, is the escape of mycobacterial bacilli into the cytosol. In 2007, van 
der Wel et al. published cryo-immunogold TEM images of Mtb-infected human 
dendritic cells and macrophages, in which Mtb was found in increasing numbers in 
the cytosol two days after infection (van der Wel et al., 2007). Recently, Mtb has been 
shown to permealize phagosomal membranes in an ESX-1-dependent manner when 
infecting macrophages (Simeone et al., 2012).  
Another class of antigen-presentation molecules involved in immune response in TB 
is the CD1 molecules (Schaible and Kaufmann, 2000). It seems that mycobacterial 
glycolipids separate from mycobacteria and are incorporated into vesicles which are 
shuttled throughout the cell and their content is presented by CD1 molecules to 
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various CD1-restricted T lymphocytes. T cells that express γδ TCR also participate in 
the immune response against M. tuberculosis (Kaufmann, 1996). Human γδ T cells are 
stimulated by a unique group of non-proteinaceous antigens containing phosphate, 
named phospholigands. Mycobacterial phospholigands, such as prenyl 
pyrophosphates, reach the cell surface through an unknown pathway and are 
recognized by γδ T cells. These four cell types act in cooperation to overcome the 
bacterial persistence. CD4 T cells are polarized into T helper cells Th1 and Th17, 
which perform effector functions producing multiple cytokines, notably IL-2 for T-
cell activation, IFN-γ and TNF-α for macrophage activation (Kaufmann, 2010).  CD8 
T cells produce IFN-γ and TNF-α to activate macrophages and they also act as 
cytolytic T lymphocytes (CTL) by secreting perforin and granulysin, which lyse host 
cells and directly attack M. tuberculosis (Kaufmann, 2010). These effector T cells are 
succeeded by memory T cells which enhance the immune response and establish its 
progression over the time. The large γδ T cell population readily produces IFN-γ 
after stimulation with phospholigands and expresses granule-dependent 
mycobacteriocidal activity. This cell type is therefore responsible for mobilizing the 
first line of defense against tuberculosis (Kaufmann, 2001; Raja, 2004). Although CD4 
T cells, CD8 T cells, γδ T cells and CD1 restricted T cells are apparently all required 
for optimum protection, a hierarchy seems to exist: CD4 T cells are the most 
important players, followed by CD8 T cells.  
T cells are the major mediators of protection, but macrophages provide the real 
effector function. The cross talk between T cells and macrophages is achieved by 
various cytokines, such as IFN-γ and TNF-α. The results of this cross talk are, first the 
macrophage activation, which means the ability of macrophages to control 
mycobacterial multiplication, for instance by generation of reactive oxygen and 
nitrogen intermediates (ROI and RNI). Secondly, cross talk is essential for 
establishment of well organized granulomas, where macrophages, dendritic cells, 
and different T cell populations exist in near vicinity. As long as this cross talk is well 
balanced, productive granulomas develop, resulting in containment of bacterial 
mass. Once any element of this complex interplay is impaired, the balance is tipped 
and the productive granuloma can no longer be sustained. In this case, bacteria 
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overcome the immune barrier and start spreading out of the granuloma. Thus, the 
active disease develops (Kaufmann, 2002). 
 
      
Fig.7  The immune response to M. tuberculosis infection  (Kaufmann, 2001). 
 
7. Vaccination strategies against tuberculosis - Present 
candidates 
Although the host immune defense is onset upon infection, M. tuberculosis is able to 
evade very successfully the immune mechanisms. The pathogen is equipped with 
numerous immune evasion strategies, including mycobacterial secreted proteins 
such as superoxide dismutase, which are antagonistic to ROI. The suppression of 
antigen presentation processes is by far the most sophisticated strategy. M. 
tuberculosis is able to decrease MHCII molecule synthesis by inhibiting the 
transcriptional regulator of this class of molecules, named CIITA (Harding and 
Boom, 2010). Cross-priming is also reduced in Mtb infection because of 
mycobacterial gene products which inhibit host cell apoptosis, such as nuoG 
(Velmurugan et al., 2007). The phagosomal localization of Mtb partially protects it 
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from MHCI antigen presentation. Understanding the mechanisms behind the evasion 
of host immune response by Mtb is the basis for rational vaccine design.  
The search for a vaccine against tuberculosis began 110 years ago. Robert Koch, eight 
years after his discovery of the tubercle bacillus (1882), devised a therapeutic vaccine 
termed tuberculin (semipurified supernatants of Mtb cultures) which completely 
failed in a large-scale clinical trial (Kaufmann and Gengenbacher, 2012). A decade 
later, the french microbiologists Albert Calmette and Camille Guérin performed a 
second attempt. After more than 200 passages, they obtained an attenuated strain of 
M. bovis, the aetiological agent of bovine tuberculosis. The two scientists proved 
safety and protection for the newly derived strain, upon intensive characterization in 
various experimental animal models (Kaufmann and Gengenbacher, 2012). The 
strain, named BCG (Bacillus Calmette-Guérin), is nowadays the only approved 
vaccine against TB. Almost three billion doses have been used since 1921. 
Approximately 115 million doses are distributed each year, covering 80% of infant 
population worldwide (Skeiky and Sadoff, 2006). BCG protects against severe forms 
of tuberculosis in newborn babies, as originally proposed by its discoverers 
(Kaufmann et al., 2010). However, the protection induced by BCG vaccination against 
adult tuberculosis is insufficient. The lack of effectiveness in adults might be 
explained considering different factors. 1) A previous exposure to environmental 
mycobacteria, very likely in endemic areas like India, interferes with the immune 
response to BCG. 2) BCG has become too attenuated through culture, and modern 
preparations of the vaccine are too benign to generate a sufficient immunity. 3) 
Clearance of BCG in some individuals may occur before development of protective 
immune response. 4) Failure of BCG to stimulate adequate anti-mycobacterial CD4 
and CD8 T cell responses (Russell et al., 2010). Nevertheless, BCG is still the only 
vaccine in use for control of the global burden of tuberculosis. BCG represents a 
starting point on which TB research is working for years with the aim to improve its 
efficacy and overcome its weaknesses.  
New anti-TB vaccination strategies can be divided into three categories. First, 
improving BCG by adding or overexpressing Mtb antigens, which would enhance 
the immune response induced by the recombinant bacterium. Second, creating 
attenuated Mtb strains by deletion of genes involved in survival or virulence of Mtb. 
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Third, the use of prime-boost strategies that amplify an initial protective immune 
response (conferred by live vaccine) by subsequent inoculation of Mtb antigens or 
protein subunits. Current pre-exposure vaccination strategies aim at reducing the 
initial M. tuberculosis bacterial burden and preventing reactivation of latent infection. 
Post-exposure vaccines are needed to target dormant bacteria and prevent their 
reactivation. They would ideally also prevent reinfection of individuals living in 
endemic areas.  
A total of 12 vaccine candidates have entered clinical trials within the last years 
(Table 1). Clinical trials for TB vaccines are divided in three phases (Kaufmann, 
2010). Phase I trials are safety and immunogenicity testing performed in small 
groups (10 or more individuals/group), typically in the region where the vaccine 
candidate was developed, and then repeated in highly endemic area. Phase II trials 
involve larger groups (100 or more individuals/group), for assessment of route of 
administration and optimal dosage. Finally, Phase III trials involve 20,000-50,000 
participants, lasting several years. They aim to assess vaccine efficacy against natural 
infection in highly endemic area. Four vaccine candidates have entered or passed 
Phase II clinical trials. Although there is still no certainty that they will confer robust 
protection against TB in humans, some look promising. Most are pre-exposure 
vaccines and will most likely prevent tuberculosis disease. They can be divided in 
three groups: live mycobacteria vaccines to replace BCG, subunits vaccines for 
booster of BCG, and killed mycobacteria vaccines as adjunct. 
Live mycobacteria vaccines to replace BCG 
Live mycobacteria vaccines are based either on improvement of BCG vaccine by 
addition of relevant genes or on attenuation of M. tuberculosis by deletion of 
virulence genes. Three recombinant BCG (rBCG) vaccines have already entered 
initial clinical trials, after assessment of higher potency and safety in preclinical 
studies, compared to the current BCG vaccine. These are rBCG30, rBCG ureC::Hly 
(VPM1002) and rBCG ureC::pfoA Rv3407+fbpB+fbpA+ (AERAS-422). The rBCG30 
overexpresses Ag85B, which is shared by BCG and Mtb, and it is the first candidate 
to show better protection in different animal models than the parental BCG (Tullius 
et al., 2008).  
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SECTION I: Candidates Tested in Clinical Trials 
Status Products Product Description Sponsors Indication 
Type of 
Vaccine 
Target 
Populations 
Phase III 
Mw [M. indicus 
pranii (MIP)] 
Whole cell saprophytic non‐TB 
mycobacterium 
Department of 
Biotechonology (Ministry 
of Science & Technology, 
Government of India), 
M/s. Cadila 
Pharmaceuticals Ltd. 
IT 
Whole cell, 
Inactivated or 
Disrupted 
– 
Phase IIb 
MVA85A/ 
AERAS‐485 
Modified vaccinia Ankara vector 
expressing Mtb antigen 85A 
Oxford‐Emergent 
Tuberculosis Consortium 
(OETC), Aeras 
B, PI, IT Viral Vectored 
BCG‐vaccinated 
infants and 
adolescents; 
HIVinfected 
adults 
AERAS‐402/ 
Crucell Ad35 
Replication‐deficient adenovirus 
35 vector expressing Mtb antigens 
85A, 85B, TB10.4 
Crucell, Aeras B Viral Vectored 
BCG‐vaccinated 
infants, children 
and adults 
Phase II 
M72 + AS01 
Recombinant protein composed of 
a fusion of Mtb antigens Rv1196 
and Rv0125 & adjuvant AS01 
GSK, Aeras B, PI 
Recombinant 
Protein 
Adolescents/ 
adults, infants 
Hybrid‐I+IC31 
Adjuvanted recombinant protein 
composed of Mtb antigens 85B and 
ESAT-6 
Statens Serum Institute 
(SSI), TBVI, EDCTP, 
Intercell 
P, B, PI 
Recombinant 
Protein 
Adolescents; 
adults 
VPM 1002 
rBCG Prague strain expressing 
listeriolysin and carries a urease 
deletion mutation 
Max Planck, Vakzine 
Projekt Management 
GmbH, TBVI 
P, B 
Recombinant 
Live 
– 
RUTI Fragmented Mtb cells Archivel Farma, S.L.. B, PI, IT 
Whole cell, 
Inactivated or 
Disrupted 
HIV+ adults, 
LTBI diagnosed 
Phase I 
AdAg85A 
Replication‐deficient adenovirus 
5 vector expressing Mtb antigen 
85A 
McMaster University P, B, PI Viral Vectored 
Infants; 
adolescents; 
HIV+ 
Hybrid‐I+CAF0
1 
Adjuvanted recombinant protein 
composed of Mtb antigens 
 85B and ESAT-6 
SSI, TBVI P, B, IT 
Recombinant 
Protein 
Adolescents, 
adults 
Hybrid 56 + 
IC31 
Adjuvanted recombinant protein 
composed of Mtb antigens 85B, 
ESAT-6 and Rv2660 
SSI, Aeras, Intercell P, B, PI 
Recombinant 
Protein 
Adolescents, 
adults 
HyVac 4/ 
AERAS‐404,  
+ IC31 
Adjuvanted recombinant protein 
composed of a fusion of Mtb 
antigens 85B and TB10.4 
SSI, sanofi‐pasteur, Aeras, 
Intercell 
B 
Recombinant 
Protein 
Infants 
AERAS‐422 
Recombinant BCG expressing 
mutated PfoA and overexpressing 
antigens 85A, 85B, and Rv3407 
Aeras P 
Recombinant 
Live 
Infants 
Phase III  
[completed] 
M. vaccae 
Inactivated whole cell non‐TB 
mycobacterium; phase III in 
BCG‐primed HIV+ population 
completed; reformulation pending 
NIH, Immodulon B, PI, IT 
Whole cell, 
Inactivated or 
Disrupted 
BCG‐vaccinated 
HIV+ adults 
Phase I  
[completed] 
rBCG30 
rBCG Tice strain expressing 30 kDa 
Mtb antigen 85B 
UCLA, NIH, NIAID, 
Aeras 
B, PI 
Recombinant 
Live 
Newborns, 
adolescents, and 
adults 
M. smegmatis Whole cell extract – B, PI, IT 
Whole cell, 
Inactivated or 
Disrupted 
– 
 
 
SECTION II: Candidates in Preclinical Studies ‐ 2011 
Type of 
Vaccine 
Products Product Description Sponsor Indication 
Recombinant 
Live 
Mtb [∆leuCD ∆panCD 
∆secA2] 
Non‐replicating, Mtb strain auxotrophic for leucine and 
pantothenate; attenuated for secA2 
Albert Einstein College of 
Medicine 
P 
MTBVAC [∆phoP, 
∆fadD26] 
Live vaccine based on attenuation of Mtb by stable inactivation 
by deletion of phoP and fadD26 genes without antibiotic 
resistance markers in compliance with 2005 and 2010 Geneva 
consensus safety requirements 
University of Zaragoza, 
Institute Pasteur, BIOFABRI, 
TBVI 
P 
Protein HBHA Naturally methylated 21‐kDa purified protein from M.bovis 
BCG 
Institute Pasteur of Lille, 
INSERM, TBVI, Aeras 
P, B, PI, IT 
DNA 
HG85A DNA vaccines—Ag85A Shanghai H&G Biotech B, IT 
Hsp DNA vaccine Codon‐optimized heat shock protein from M. leprae, a CpG 
island 
Sequella, Shanghai Public 
Health Clinical Center 
B, PI, IT 
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Table 1. In Section I are described the candidates currently tested in clinical trials. In the Section II are 
listed the candidates involved in preclinical studies. P: Prime; B: Boost; PI: Candidate is indicated post-
infection; IT: Candidate is indicated for immunotherapy  (Source: Stop TB Partnership, 2011). 
 
This vaccine has successfully completed Trial I, showing a comparable safety profile 
to the parental BCG strain and a proof-of-principle that recombinant BCGs 
overexpressing immunodominant Mtb antigens are a promising approach (Rowland 
and McShane, 2011).The rBCG ureC::Hly is a recombinant strain that secretes 
lysteriolysin produced by Listeria monocytogenes and carries a deletion of ureC gene 
(Grode et al., 2005). Listeriolysin is a pore-forming toxin protein which exerts its 
activity only at acidic pH. To maintain acidic pH in BCG phagosome, the urease gene 
(ureC), contributing for pH neutralization of the phagosome, was deleted. The 
recombinant bacterium therefore secretes active lysteriolysin, which by punching 
holes in the phagosome membrane, determines two consequences. First, perforation 
of the membrane facilitates translocation of mycobacterial antigens into the cytosol 
and subsequent MHCI loading. Second, membrane perforation promotes leakage of 
phagolysosomal proteases such as cathepsins into the cytosol, activating caspase 
cascade-inducing apoptotic cell death. Apoptosis in turn results in cross-priming of 
mycobacterial antigens. The potent MHCI presentation, enhancement of apoptosis, 
increased cross-priming and uptake by dendridic cells, result in increased CD8 and 
CD4 T-cell responses as well as γδ T-cell and CD1-restricted T cell activation. This 
vaccine is thought to overcome some weaknesses of BCG vaccine such as ineffective 
CD8 T cell stimulation and poor apoptosis induction in infected macrophages. In 
preclinical mouse-protection studies, rBCG ureC::Hly induced superior protective 
efficacy than the parental strain against Mtb challenge, along with higher safety 
profile in immuno-compromised SCID mice. Moreover, unlike the parental BCG 
strain, rBCG ureC::Hly was demonstrated to protect significantly against the virulent 
M. tuberculosis Beijing/W strain (Grode et al., 2005). A Phase I clinical trial evaluating 
the safety and immunogenicity of this vaccine in healthy male volunteers has been 
completed and a dose-escalation RCT (randomized controlled trial) in South Africa is 
ongoing (Rowland and McShane, 2011). 
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The rBCG ureC::pfoA Rv3407+fbpB+fbpA+ combines concepts underlying VPM1002 and 
rBCG30 (Sun et al., 2009). It overexpresses the immunodominant antigens Ag85A 
(fbpA), Ag85B (fbpB) and Rv3407, which has been associated with latent TB. Here the 
recombinant bacterium expresses another type of pore-forming component, which is 
PFO, the perforin of the extracellular bacterium Clostridium perfringens. Shrewdly, 
PFO has been engineered by a single amino acid exchange to maintain hemolytic 
activity at pH 7.0. This strain combines the increased protection seen with rBCG30 
with the increased protection and safety of the endosome-escape mutants. A Phase I 
clinical trial to evaluate safety in adults had to be terminated because two vaccinated 
trial participants developed shingles, probably due to reactivation of dormant herpes 
varicella–zoster virus. A careful elucidation of underlying mechanisms of this 
vaccine is therefore required (Kaufmann and Gengenbacher, 2012). 
Vaccines based on M. tuberculosis attenuation have to carry at least two independent 
deletions in order to avoid spontaneous conversion to virulence. The most promising 
candidates are Mtb ∆RD1∆panCD and Mtb ∆phoP∆fad. The first is devoid of the 
entire Mtb virulence gene island RD1 (region of difference one) and auxotrophic 
because of pantothenate deficiency (Sambandamurthy et al., 2006). The RD1 genomic 
region is present in all virulent strains of M. tuberculosis, and missing from the 
vaccine strain M. bovis BCG (Ganguly et al., 2008). RD1 has been considered crucial in 
the pathogenesis of M. tuberculosis. It encodes part of the ESX-1 secretion system and 
some of its substrates, e.g. the two secretory proteins CFP-10 and ESAT-6 (Guinn et 
al., 2004). The ∆RD1∆panCD double deletion mutant of M. tuberculosis H37Rv was 
more attenuated and efficacious as a vaccine than was BCG, when assessed in 
immunocompromised mice (Sambandamurthy et al., 2006). In the mutant Mtb 
∆phoP∆fad, inactivation of PhoP, which regulates expression of many Mtb proteins, 
along with the deletion of fad gene, essential for the phthiocerol dimycocerosate 
synthesis, attenuate M. tuberculosis virulence while maintaining the immune 
response normally associated with the parental strain (Martin et al., 2006). These 
vaccines are expected to enter clinical trials in the next few years (Kaufmann et al., 
2010).  
In order to improve efficacy of BCG replacement candidates, some strategies have 
already been planned for the near future. Introduction of genes encoding dormancy 
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antigens such as the DosR-regulated gene products might be an approach for post-
exposure vaccination of latently infected individuals. Expression of cytokines genes 
such as IL-18 and IFN-γ could enhance Th1 cell polarization. Deletion of anti-
apoptotic genes is a potential powerful strategy for facilitating cross-priming. A 
promising vaccine candidate for long-term protection is the recently generated rBCG 
ureC::Hly expressing latency-associated antigens, such as Rv2659c, Rv3407 and 
Rv1733c. The expression of these three latency-associated antigens significantly 
improved protection in mice after intra-dermal vaccination at day 200 p.i. (Reece et 
al., 2011).  
Subunits vaccines for booster of BCG 
Seven candidates are subunit booster vaccines to be given on the top of the BCG 
prime. Subunit vaccine candidates are based on antigens that activate T cells in 
previously vaccinated humans and animals. Two types of product have been 
developed: recombinant fusion proteins consisting of two or three dominant Mtb or 
BCG antigens and live viral vectors expressing one or several mycobacterial proteins. 
The limiting factors of these approaches are that the first type needs an adjuvant to 
promote Th1 immune response, whereas the second type can be inhibited by 
previous exposure to the vector. Subunits vaccines trigger a Th1-dominated immune 
response to the expressed heterologous antigen and induce CD8 T-cell response 
(Kaufmann et al., 2010). 
Ag85B-ESAT-6 (H1) candidate vaccine was designed with a strong Th1 adjuvant, 
IC31. This adjuvant is a mixture of oligodeoxynucleotides, that stimulate dendridic 
cells, and polycationic amino acids, that increase antigen uptake by APC (Antigen-
Presenting Cell). The vaccine has been assessed in two Phase I clinical trials, 
demonstrating high tolerability and immunogenicity in humans. In fact, it was 
shown to induce a strong persisting Th1 response to the Mtb Ag85 protein, without 
interfering with ESAT-6-based diagnostic assays performed a few months after 
immunization. The same fusion protein was also used for formulation with a novel 
liposomal adjuvant, CAF01, giving rise to durable, multifunctional Th1 T-cell 
responses and protection against Mtb aerosol challenge in mice (Rowland and 
McShane, 2011). An alternative fusion protein was developed, replacing ESAT-6 with 
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TB-10.4 (esxH), to reduce the putative risk of interference with diagnostic tools. The 
vaccine was named Ag85B-TB-10.4 (AERAS-404). 
M72 is a recombinant fusion of Mtb39 and Mtb32 proteins, formulated in the vaccine 
adjuvant system AS02A, which is an immuno-potentiator composed of 
monophosphoryl lipid A, an immuno-stimulant, and the detergent QS21. The two 
fusion proteins were selected for their ability to induce IFN- γ production by both 
CD4 and CD8 T-cells. The vaccine completed Phase I and II, showing acceptable 
tolerability and profound T-cell responses in healthy adults (Von Eschen et al., 2009). 
MVA85A is a recombinant, replication-deficient vaccinia virus, expressing Ag85A. 
The promising safety and immunogenicity of this candidate vaccine that arose from 
the Phase I clinical trials in UK led to further Phase I and IIa clinical trials in target 
populations in South Africa, The Gambia and Senegal (Rowland and McShane, 2011; 
Sander et al., 2009). 
Ad35 (AERAS-402) and AdAg85A are replication-deficient recombinant 
adenoviruses (Ad35 and Ad5, respectively) expressing Ag85A, Ag85B and TB10.4 
and solely Ag85A, respectively (Radosevic et al., 2007; Santosuosso et al., 2006). These 
vaccines are of special interest for their excellent ability to stimulate CD8 T-cells. The 
counterpart is the diminished effectiveness due to a previous exposure to a 
homologous or cross-reacting strain of adenovirus. This event is quite likely, since 
Adenovirus 5 is highly prevalent in the human population, while Adenovirus 35 has 
a fairly low prevalence (ranging from 5% in developed countries to 20% in Africa) 
(Kaufmann et al., 2010). 
Killed mycobacteria vaccines as adjunct 
The rationale of the therapy based on killed mycobacteria vaccines is first to take 
advantage of the bactericidal properties of chemotherapy to kill active growing 
bacilli and reduce local inflammatory responses. After chemotherapy, killed 
mycobacteria can be inoculated to reduce the probability of re-growth of the 
remaining latent bacilli. 
Whole heat-killed M. vaccae, an environmental saprophyte, has been developed as an 
immuno-therapeutic agent against tuberculosis (Dlugovitzky et al., 2006). The 
vaccine is usually given intradermally in a multidose series. Variable results have 
been obtained in different geographical locations within African continent. Clinical 
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studies show that it might improve radiological and clinical outcomes, but the 
discrepant results led the vaccine to be evaluated as a prophylactic vaccine 
(Kaufmann et al., 2010) .  
RUTI is another proposed therapeutic vaccine candidate. M. tuberculosis is grown 
under stress conditions and bacilli are then fragmented, detoxified, and delivered in 
liposomes (Cardona, 2006). In a Phase I clinical trial in Spain it showed promising 
results, but it still has to be evaluated in TB positive individuals (Rowland and 
McShane, 2011). 
 
Three types of vaccines are ideally to be considered in a comprehensive tuberculosis 
vaccination strategy (Kaufmann et al., 2010). First, an improved BCG vaccine should 
prime the immune system, meaning stimulation of T cells that are subsequently 
ready to be re-stimulated by boost vaccination. In case of early tuberculosis exposure, 
such a vaccine would at least slow down bacterial growth, reduce bacterial burden 
and therefore protect against tuberculosis disease. After a few weeks to several years, 
a subunits vaccine should be given. The aim would be to boost and re-orient the 
BCG-induced memory response. Such boosting might have to be repeated during an 
individual’s lifespan, with changing antigen composition. To target latent infection 
and prevent reactivation of dormant Mtb, a post-exposure vaccine should be given to 
adolescent and adults carrying a latent TB infection. This last category of vaccines are 
less well advanced than the pre-exposure ones, and the present state-of-art of post-
exposure vaccines entering clinical trials in 2010 includes one candidate: Hybrid 56, a 
formulation of the Ag85B-ESAT-6 with the addition of the dormancy antigen Rv2660 
in IC31 (Kaufmann et al., 2010).  
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PART I – Structural and biochemical characterization 
of the M. tuberculosis zinc metallopeptidase Zmp1 and 
identification of potential substrates 
 
1. Overview 
The broad arsenal of virulence factors of M. tuberculosis is still poorly characterized. 
Recently, a new virulence determinant involved in the phagosome maturation arrest 
was revealed, the zinc metallopeptidase Zmp1. The peptidase was described as an 
important player in pathogenesis, and in the host immune response to M. 
tuberculosis. Due to its key role in mycobacterial virulence, Zmp1 represents an 
attractive target protein to investigate. The knowledge of this virulence factor is the 
prerequisite for exploiting it as putative drug target and for rationale vaccine 
development. The subject of the Part I is the functional and structural 
characterization of Zmp1. The zinc metallopeptidase Zmp1 was extensively 
investigated from biochemical and structural point of views, aiming to achieve the 
broadest knowledge about this virulence factor. The crystal structure of Zmp1 was 
resolved, and similarities with other eukaryotic peptidases have been revealed. In 
parallel, the biochemical and enzymatic properties of Zmp1 were studied. The 
question of which are the substrates targeted by Zmp1 was addressed. The Zmp1 
substrate specificity was determined and several in vitro substrates have been 
described.  
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ABSTRACT 
Mycobacterium tuberculosis, the causative agent of tuberculosis, parasitizes host 
macrophages. The resistance of the tubercle bacilli to the macrophage hostile 
environment relates to their ability to impair phagosome maturation and its fusion 
with the lysosome, thus preventing the formation of the phago-lysosome and 
eventually arresting the process of phagocytosis. The M. tuberculosis zinc-dependent 
metalloprotease Zmp1 has been proposed to play a key role in the process of 
phagosome maturation inhibition and emerged as an important player in 
pathogenesis. Here, we report the crystal structure of wild-type Zmp1 at 2.6 Å 
resolution in complex with the generic zinc metalloprotease inhibitor 
phosphoramidon, which we demonstrated to inhibit the enzyme potently. Our data 
represent the first structural characterization of a bacterial member of the zinc-
dependent M13 endopeptidase family and revealed a significant degree of 
conservation with eukaryotic enzymes. However, structural comparison of the 
Zmp1-phosphoramidon complex with homologous human proteins neprilysin and 
endothelin-converting enzyme-1 revealed unique features of the Zmp1 active site to 
be exploited for the rational design of specific inhibitors that may prove useful as a 
pharmacological tool for better understanding Zmp1 biological function.  
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INTRODUCTION 
The intracellular pathogen Mycobacterium tuberculosis is the main etiological agent of 
human tuberculosis (TB), one of the world's deadliest diseases. According to the 
World Health Organization 2010 Fact Sheet, one third of the world population is 
exposed to M. tuberculosis, and 9 million people develop active TB, with 2 million 
deaths per year. The already high TB global burden is further exacerbated by the 
high mortality rate of TB-infected individuals suffering from HIV/AIDS. Moreover, 
the pharmacological treatment of TB is long and expensive, and misuse of first-line 
and second-line drugs against TB can favor the development of multidrug-resistant 
or extensively drug resistant M. tuberculosis strains, rendering extremely difficult the 
eradication of the pathogen by the most effective anti-TB drugs (2).  
The host organism deals with M. tuberculosis infection by a series of innate and 
adaptive immune responses (3). Inhaled M. tuberculosis bacteria are phagocytosed by 
resident macrophages in the lungs, i.e. the alveolar macrophages, but not efficiently 
cleared (4). In immunocompetent individuals the initial acute infection is controlled 
by the immune system, and living bacteria are confined in a peculiar localized 
pulmonary structure called granuloma. There, the bacteria can endure indefinitely in 
a latent, nonvirulent form, and are reactivated whenever an immunosuppressive 
condition occurs (5).  
A key step for successful bacterial clearance by macrophages is phagosome 
maturation process, which culminates in the formation of the phago-lysosome (6). 
However, some pathogens, among them M. tuberculosis, have evolved the ability to 
preclude the macrophages killing by inhibiting the phagosome maturation process 
(7, 8). This step is critical for the progression of the infection because it compromises 
bacterial clearance (9) and antigen processing (10, 11). Master et al. (12) proposed that 
M. tuberculosis is able to suppress phagosome maturation by inhibiting the 
inflammasome (13). The inflammasome is a multiprotein complex composed by 
members of the cytosolic sensor proteins family called nucleotide binding 
oligomerization domain which, once activated upon recognition of pathogen-
associated molecules in the extracellular or the intracellular compartment, drives the 
activation of pro-caspase-1 (14, 15). Activated caspase-1, in turn, proteolitically 
activates pro-IL-1β into IL-1β, which, once secreted, in an autocrine and paracrine 
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fashion triggers the phagosome fusion with intracellular lysosomes and the early 
inflammatory response (16).  
Master et al. found that zmp1 gene (Rv0198c) suppresses inflammasome activation by 
inhibiting caspase-1 activation, thus preventing processing of pro-IL-1β into IL-1β 
and the consequent phagosome maturation. Nonetheless, they furnish evidence that 
suppression of the zmp1 gene reestablished the activation of caspase-1, the 
production of IL-1β, and the full maturation of the phagosome into phago-lysosome, 
leading to the clearance of the pathogen. In addition, the authors showed that 
exogenously added IL-1β was sufficient to determine bacteria clearance by the 
phago-lysosome. The authors therefore proposed that the blocking of the phagosome 
maturation process is due to the inhibition of the inflammasome by the secreted M. 
tuberculosis protein Zmp1 (Zn-dependent metalloprotease-1).  
In contrast to what was proposed by Master et al., a recent report by Muttucumaru et 
al. (17) claims that deletion of the zmp1 gene causes bacterial hypervirulence in a 
mouse model. This differs from what was observed previously by Master et al., 
where zmp1 deletion led to virulence attenuation. However, these two reports 
suggest a key role of Zmp1 during M. tuberculosis pathogenicity, although its 
mechanism of action still remains under debate.  
BLAST and Pfam sequence analysis indicated that Zmp1 is an M13 endopeptidase, a 
protein family present in a wide range of organisms including mammals and 
bacteria, with the exception of yeast (18). M13 endopeptidases regulate the biological 
activity of many hormones and peptides and are involved in many important 
processes such as blood pressure regulation (neprilysin, or NEP) (19), cardiovascular 
development (endothelin-converting enzyme-1, or ECE-1) (20), prevention of 
hemolytic reaction (KELL) (21) and phosphate homeostasis (PHEX) (22). M13 
endopeptidases are type II, single-pass transmembrane zinc-metallopeptidases with 
a hydrophobic N-terminal section of about 20 amino acids spanning the cytoplasmic 
membrane, and a large ectodomain of about 700 residues. Sequence analyses indicate 
that Zmp1, unlike NEP and ECE-1 and other members of the M13 family, lacks the 
N-terminal sequence required for extracellular export (although Zmp1 has been 
found in cell supernatants) (12) and the hydrophobic segment providing cell 
membrane anchoring.  
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All M13 endopeptidases are characterized by three signature motifs involved in the 
binding of Zn2+ (HEXXH and EXXXD) and substrate/inhibitor (VNAXY). The 
glutamate residue of the HEXXH signature fingerprint is essential for catalysis 
because it polarizes the water molecule that facilitates the nucleophilic attack to the 
substrate peptide bond (23).  
To shed light on the so far uncharacterized process of inflammasome inhibition by 
M. tuberculosis, we solved the crystal structure of Zmp1 in complex with the inhibitor 
phosphoramidon. Our structural data reveal a significant structural conservation 
with human zinc-dependent metalloproteases NEP (24) and ECE-1 (25), thus 
identifying M. tuberculosis Zmp1 as a new member of M13 Zn-dependent 
metalloproteases. However, subtle differences are present in the catalytic site of 
Zmp1 that could be exploited for the design of specific inhibitors against the 
mycobacterial enzyme.  
 
EXPERIMENTAL PROCEDURES 
Protein Expression and Purification - Full-length zmp1 was cloned in pET100/d-TOPO® 
vector (providing an N-terminal enterokinase-cleavable His tag) and expressed in 
Escherichia coli BL21 (DE3) cells. Bacteria were precultured overnight in 2× TY 
medium and then diluted in 1 liter of 2× TY medium. The absorbance (A) was 
constantly monitored until it reached 0.6. The temperature was then shifted to 20 °C, 
and protein expression was induced overnight by the addition of 0.5 mM isopropyl 
1-thio-β-d-galactopyranoside. The cells were pelleted and resuspended in 30 ml of 1× 
PBS, pH 7.4, and lysed using a mechanical disruption system (Basic Z apparatus; 
Constant System). Pellet and supernatant were separated by centrifugation, and the 
supernatant was applied to a preequilibrated nickel-nitrilotriacetic acid column 
(Qiagen) and incubated for 1 h at 4 °C. Resin was washed thoroughly with 1× PBS, 
pH 7.4, and protein was eluted with a step gradient of imidazole. Protein eluted in 
100 and 200 mM imidazole fractions.  
The eluted protein was then diluted in 10 mM Tris, pH 8, buffer and loaded on a 
Mono Q 5/50 column (GE Healthcare) and washed thoroughly. Protein elution was 
performed applying a linear gradient of NaCl. Fractions containing the purified 
protein were concentrated and loaded on a Sephacryl 200 16/60 gel filtration column 
 56
pre equilibrated with 10 mM Tris, pH 8. Zmp1 eluted as a monomer with a 
symmetric peak. Fractions containing Zmp1 were pooled and used immediately for 
crystallization or flash frozen in liquid nitrogen and stored at −80 °C.  
Protein Crystallization and Structure Solution - Purified Zmp1 was concentrated to 26 
mg/ml using Vivaspin concentrators (Sartorius AG) with a molecular mass cut-off of 
50 kDa. Phosphoramidon ((N-(α-rhamnopyranosyl-oxyhydroxy-phosphinyl)-l-
leucyl-l-tryptophan); catalog no. R9382, Sigma) was then added to the concentrated 
protein to a final concentration of 1 mM. Protein concentration of 13 mg/ml was 
obtained by mixing the phosphoramidon-complexed Zmp1 with gel filtration buffer 
in a 1:1 ratio. Initial crystallization screens were performed with an Oryx4 Protein 
Crystallization Robot (Douglas Instruments Ltd.). First Zmp1 crystals were obtained 
using the Hampton Crystal Screen 2. Optimized diffraction quality crystals were 
obtained by mixing 0.3 µl of reservoir solution (0.2 M ammonium sulfate, 0.1 M 
sodium acetate trihydrate, pH 4.6, 30% w/v polyethylene glycol monomethyl ether 
2000) with 0.3 µl of phosphoramidon-complexed Zmp1 concentrated at 13 mg/ml 
and were grown for 2 months at 20 °C. Crystals were fished, cryoprotected with 30% 
glycerol, and flash frozen in liquid nitrogen. Best crystal diffracted to 2.60 Å at ID14-
EH1 beamline (Electrosynchrotron Research Facility, Grenoble). Data were processed 
using MOSFLM (26) and scaled using SCALA (27). Molecular replacement was 
performed using PHASER (28) included in the PHENIX package (29) and using the 
structure of NEP as the search model (Protein Data Bank ID code 1DMT). Automatic 
model building was performed using AUTOBUILD of the PHENIX suite, allowing 
the fitting of 90% of residues. The remaining residues were added manually.  
Structure and sequence alignments relative to Fig. 1 were performed using 3DCoffee 
(30) and ClustalW (31), respectively, and edited with ESPript (32).  
Structure was refined using COOT (33) and REFMAC (34) by applying TLS 
refinement to model data anisotropy. Zmp1 structure was analyzed and validated 
using MOLPROBITY (35). All molecular graphics images were produced using 
PyMOL (36) with the exception of Fig. 2C, prepared using the UCSF Chimera 
package (37).  
PDB Deposition - The coordinates and the structure factors were deposited in the 
Protein Data Bank under ID code 3ZUK.  
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Determination of Phosphoramidon Inhibition Constant - Phosphoramidon inhibition 
constant Ki was determined by following the inhibition of Zmp1 catalytic activity 
toward the generic fluorogenic substrate for matrix metalloproteinases (MMPs) 
MMP2/MMP7. This substrate consists of the amino acid sequence PLGL flanked by 
the fluorophore/quencher system methoxycoumarin/dinitrophenyl-alanine-arginine 
(full sequence: MCA-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2; MCA stands for (7-
methoxycoumarin-4-yl)-acetyl; Dpa stands for N-3-(2,4-dinitrophenyl)-l-2,3-
diaminopropionyl. MCA is the fluorophore, Dpa the quencher (MMP2/MMP7 
product number 03-32-5032, Calbiochem). Several phosphoramidon concentrations, 
ranging from 15 to 250 nM, were incubated with 0.5 nM Zmp1 in 100 mM Tris-HCl, 
0.1% borate, 150 mM NaCl, and 10 mM CaCl2, pH 8.0, buffer at 37 °C. The 
fluorescence was detected in an Eclypse fluorometer (Varian) (excitation 320 nm, 
emission 395 nm). The inhibition constant Ki was calculated upon determination of 
the various Km values from the substrate concentration dependence at several 
inhibitor concentrations and then plotting data of Km as a function of inhibitor 
concentration, as from the following equation.  
 
 
 
RESULTS 
Zmp1 Overall Structure and Active Site 
Zmp1 was recombinantly expressed in E. coli, purified to homogeneity and co-
crystallized with the inhibitor phosphoramidon, a metabolite of Streptomyces 
tanashiensis and a known broad spectrum inhibitor of Zn-dependent 
metalloproteases (38, 39). This molecule is able to inhibit in a competitive fashion (at 
least up to a concentration of 0.25 µM) the enzymatic activity of Zmp1 toward the 
synthetic substrate MMP2/MMP7 with a Ki of 35 ± 5 nM (see supplemental Fig. 1). 
Orthorhombic crystals diffracted to 2.60 Å and contained two Zmp1 molecules in the 
asymmetric unit. The structure of Zmp1 was solved by molecular replacement using 
NEP as the search model. Automatic and manual model building led to a refined 
model with R and Rfree factors converging to 17.51 and 24,96, respectively. Data 
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collection and refinement statistics are summarized in Table 1. Zmp1 shares 31% 
homology and 48% similarity with both human NEP and ECE-1 (Fig. 1) onto which it 
can be superimposed with a root mean square deviation of 1.87 Å and 1.73 Å for 593 
and 594 Cα pairs, respectively. Zmp1 has two cysteines (Cys285 and Cys629), whereas 
NEP has 12 and ECE-1 14. Cys428 of human ECE-1 (Cys412 in rat ECE-1) is involved in 
vivo in the formation of an intermolecular disulfide bond responsible for ECE-1 
dimerization (40). Zmp1, like NEP, is monomeric in solution (Ref. 24 and present 
work; data not shown), and its two cysteines are not involved in a disulfide bridge.  
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FIGURE 1. Structure and sequence alignments of M. tuberculosis Zmp1 with human NEP and ECE-
1. Spirals and arrows indicate helices and β-strands, respectively. Red boxes with white characters 
indicate residue identity; red characters indicate residue similarity; blue-framed characters indicate 
similarities between groups of residues. Residues that bind Zn2+ are shown in yellow and labeled with 
a triangle. Residues that interact with phosphoramidon are shown in green and labeled with a black 
circle. Catalytic Glu494 is shown in cyan and labeled with a white circle. The two Arg residues of Zmp1 
that make contact with TEA are colored black on a yellow background and are labeled with a star; the 
corresponding nonconserved NEP and ECE-1 residues are colored white on a black background.  
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The structure of Zmp1 presents an oval shape with dimensions of about 78 Å for the 
major axis and 60 Å for the minor one. Overall, the structure is composed by two 
mainly α-helical lobes interconnected by several loops distributed over the protein 
equatorial line (Fig. 2, A and B). The enzyme catalytic site is located between the two 
lobes and is accessible via two oppositely positioned small openings on the protein 
surface (Fig. 2C). The catalytic zinc ion is coordinated in a tetrahedral geometry by 
the conserved residues His493 (2.2 Å) and His497 (2.0 Å), belonging to the signature 
motifs 493HEXXH497, by Glu560 (2.0 Å), part of the 560EXXXD564 signature fingerprint, 
and by the O1 oxygen of the N-phosphoryl moiety of the inhibitor (2.0 Å, Fig. 3A). 
The conserved residue Glu494 (HE494XXH), unlike Glu560, is not involved in metal 
coordination. Instead, its OE1 atom forms a specific interaction with the O2 of the 
phosphoramidon N-phosphoryl group. This oxygen atom occupies the position of 
the water molecule responsible for the nucleophilic attack to the peptide substrate, as 
observed for other M13 family enzymes (23). Thus, the substitution of the catalytic 
water molecule with the phosphoramidon n-phosphoryl O2 atom allows inhibition of 
Zmp1 catalysis. 
 
 
 
 
FIGURE 2. A, overall structure of Zmp1. Colors are coded according to secondary structure and lobe 
location. Blue and red, α-helices, upper and lower lobe, respectively; orange and yellow, β-sheets, upper 
and lower lobe, respectively; dark gray, loops. Phosphoramidon and TEA are shown in sticks. Zn2+ is 
shown as a gray sphere. B, rotation of Zmp1 90 °C clockwise along the vertical axis. C, section of Zmp1 
showing electrostatic surface potential. In blue, positive charges; in red, negative charges. Arrows 
indicate surface holes and cavities for product/substrate access to the catalytic site. 
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FIGURE 3. Interactions of Zmp1 (chain A) with zinc (A) phosphoramidon (B), and TEA (C). Zmp1 
residues are rendered in dark gray sticks. Phosphoramidon and TEA and the corresponding electron 
densities are colored orange and yellow, respectively. Electron densities are contoured at 1.4 σ.  
 
Zmp1 Interactions with the Inhibitor Phosphoramidon 
In the catalytic site, electron density compatible with the inhibitor molecule 
phosphoramidon was observed. Phosphoramidon is held in place by an intricate 
network of interactions with Zmp1 (Fig. 3). The indole moiety of phosphoramidon l-
tryptophan makes ̟-stacking interaction with Phe48, whereas the indole NH group 
forms a hydrogen bond with Val451 main chain carbonyl group and Asn452(ND2), 
both belonging to the conserved triad 451VNA453 (Fig. 3B). OD1 and ND2 groups of 
Asn452 are hydrogen-bonded with the inhibitor l-tryptophan and l-leucyl NH groups. 
The latter is also involved in hydrogen bonding with Ala453 main chain carbonyl 
group and Glu494 OE2. Additionally, the conserved Arg628 forms hydrogen bonds 
with main chain l-aspartyl carbonyl group. The inhibitor rhamnose moiety does not 
make contacts with the protein and is exposed to the solvent.  
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Zmp1 Interactions with N,N′,N"-Triethanolamine (TEA) 
Further electron density has been detected in close proximity to the phosphoramidon 
molecule and has been interpreted as TEA (Fig. 3, B and C). Because TEA was not 
added to any buffer used along the purification and crystallization procedures, we 
speculate it could likely be a contaminant of the phosphoramidon preparation. This 
molecule is observed only in one of the two Zmp1 subunits of the asymmetric unit 
(chain A) whereas in the other (chain B) is replaced by three water molecules 
matching the positions of the TEA hydroxyl groups of chain A. The TEA binding 
pocket is located within the catalytic site and the molecule forms stabilizing 
interactions both with the protein and the inhibitor phosphoramidon. All three 
hydroxyl groups of TEA make hydrogen bonds with both phosphoramidon and 
Zmp1 side chains: O3 with the NH2 of the nonconserved Arg615, O7 with NH and the 
carboxylic group of the l-tryptophan, and O10 with O2 of the phosphoramidon 
rhamnose moiety. Additionally, the central amine group of TEA makes a hydrogen 
bond with the nonconserved Arg616 (NH1).  
Zmp1 Recognition Subsites 
The S1 recognition subsite of Zmp1 accommodates the rhamnose moiety of the 
inhibitor (Fig. 4, A and B). Residues Tyr454 and Met446 do not interact with the 
phosphoramidon rhamnose group, leaving it mostly exposed to the solvent. These 
residues are conserved in ECE-1 (Tyr568 and Met560), whereas in NEP they are 
replaced by Phe544 and Ser536. The S1′ subsite of Zmp1 is constituted mainly by 
hydrophobic residues, as observed also in NEP and ECE-1 (Fig. 4, C and D). In 
Zmp1, residue Ala489 (Val603 in ECE-1) is replaced in NEP by a Met579, making the 
Zmp1 S1′ subsite more hydrophobic compared with that of NEP. The indole moiety 
of the inhibitor makes ̟-stacking interaction with the conserved Phe48 of Zmp1 
(Phe106 and Phe149 in NEP and ECE-1, respectively). All of the other residues of the 
S1′ subsite (Val490, Ile468, Phe473, Ile603, and Trp604) do not interact with the inhibitor 
and form a mostly hydrophobic pocket that presumably accommodates a substrate 
with a large, hydrophobic P1′ side chain.  
The large S2′ subsite of Zmp1 is the least conserved among that of NEP and ECE-1 
(Fig. 4, E and F). Only two residues of Zmp1 are conserved in NEP and ECE-1: Phe48 
and Trp604 (Phe106/Phe149 and Trp693/Trp714 in NEP/ECE-1, respectively). In Zmp1, 
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the hydrophobic Phe52 residue is replaced in NEP by the charged, flexible residue 
Arg110 and in ECE-1 by the bulky residue Trp153. Zmp1 residues Arg45 and Asp49 are 
substituted in NEP by Tyr103 and Asp107, respectively. The small, charged Zmp1 
residues Thr44 and Thr606 are replaced in NEP by Arg102 and Gly695. Finally, Ser608 is 
changed in Tyr697 in NEP and in Arg718 in ECE-1. All of these mutations not only alter 
the local charge and hydrophobicity, but also vary the accessible volume of the 
subsite. The differences among Zmp1, NEP, and ECE-1 S2′ subsites may be relevant 
for the specificity of their respective natural substrate(s).  
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FIGURE 4. Comparison of Zmp1 S1, S1′, and S2′ subsites with NEP and ECE-1. A, Zmp1 (gray) and 
NEP (pink) S1 subsite. B, Zmp1 (gray) and ECE-1 (violet) S1 subsite. C, Zmp1 (gray) and NEP (pink) S1′ 
subsite. D, Zmp1 (gray) and ECE-1 (violet) S1′ subsite. E, Zmp1 (gray) and NEP (pink) S2′ subsite. F, 
Zmp1 (gray) and ECE-1 (violet) S2′ subsite. Phosphoramidon molecule is colored in orange.  
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DISCUSSION 
We report here the crystal structure of Zmp1 from M. tuberculosis, a potential 
pharmacological target against tuberculosis. It is to our knowledge the first crystal 
structure of a prokaryotic M13 protease. Zmp1 shows significant structural similarity 
with the human homologous proteins NEP and ECE-1 regarding the overall 
molecular architecture, the structural arrangement, and the mode of binding 
observed in complex with the inhibitor phosphoramidon. Residues forming the S1 
subsite of Zmp1 are identical to those of ECE-1 but differ from those of NEP (Tyr454 
and Met446 of Zmp1 are replaced by Phe544 and Ser536 in NEP). The local increased 
hydrophobicity of Zmp1 compared with the NEP S1 subsite could indicate a higher 
affinity for inhibitors carrying hydrophobic groups at the P1 site, as observed for 
ECE-1 (41, 42). However, the S1 site leaves the rhamnose moiety of the inhibitor 
exposed to the solvent and plays a minor role in substrate selectivity, as reported for 
NEP and ECE-1 (43–46). The S1′ subsite is highly conserved among Zmp1, NEP, and 
ECE-1. The residues present in this subsite are all hydrophobic with the exception, in 
NEP, of Met579 (Ala489/Val603 in Zmp1/ECE-1, respectively). The slight difference in 
volume and hydrophobicity of the S1′ site resulting from this single mutation may 
explain the moderate preference, for ECE-1, of inhibitors carrying a bulky 
hydrophobic group at the P1′ site (1, 47, 48). A similar behavior could be envisaged 
also for Zmp1, as its S1′ subsite is entirely hydrophobic. Residues of the S2′ subsite 
are less conserved compared with those of the S1 and S1′ subsites. Understanding the 
mechanism of S2′ subsite specificity would be useful for the individuation of 
structural criteria that would serve as the rational basis for the design of specific 
Zmp1 inhibitors. The Zmp1 structure presented here bears in the catalytic pocket a 
molecule that we identified as TEA. In the crystal structure of NEP (24), a glycerol 
molecule occupies a position equivalent to that observed for TEA in Zmp1 and, like 
TEA, interacts both with NEP and phosphoramidon. Because TEA and glycerol are 
two structurally different molecules that bind to an equivalent pocket, we speculate 
that such a structural trait might be of relevance in the family of M13 
metalloproteases for binding/recognition of nonsubstrate molecules possibly with 
regulatory role. It should also be noticed that such a secondary binding pocket shows 
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peculiar features in different members of the M13 family (Fig. 1). In particular, in 
Zmp1, TEA interacts with two Arg residues (Arg615 and Arg616) that are structurally 
nonconserved in human NEP and ECE-1-homologous proteins (Fig. 1). Therefore, the 
TEA binding pocket emerges as a promising docking site for the structure-based 
design of specific Zmp1 inhibitors. A matter of recent debate is the role played by 
Zmp1 in M. tuberculosis pathogenesis. A recent paper (17) shows that zmp1-deleted 
M. tuberculosis strains are hypervirulent, which contrasts with the work of Master et 
al. (12), as they propose that zmp1 deletion leads to virulence attenuation. Although 
the issue awaits a definitive answer, the structure of Zmp1 reported here will help 
the developing of specific inhibitors that may prove useful both as a tool for further 
investigation of the biological functions of Zmp1 and as compounds of potential 
pharmaceutical interest.  
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SUPPLEMENTAL DATA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1. Phosphoramidon concentration dependence of MCA substrate 
affinity constant Km for Zmp1 at pH 8.0 and 37°C. Values of Km were obtained by 
Lineweaver-Burk plot of fluorogenic MCA peptide cleavage in the presence of 0.5 nM Zmp-1 
in the absence and presence of different Phosphoramidon concentrations. The continuous 
line is the non-linear least-squares fitting of data according to Eq. (1), from which a value of 
0Km =  4.8(±0.7) × 10-6 M and a value of KI = 3.5(±0.5) x 10-8 M are obtained. 
 
 
 
 
 
 71
3. Application of the proteomic approach 2D-PAGE for Zmp1 substrate 
identification 
 
INTRODUCTION 
Proteomics is the large-scale, systematic study of proteins, particularly their 
functions, modifications, interactions and localization. Usually, the tools of 
proteomics are applied to investigate modifications induced during the course of cell 
differentiation, activation or transformation. The proteolysis, a key regulatory post-
translational modification in diverse cellular processes, is a privileged model for this 
type of study. Indeed, proteomic approaches permit to track proteolytic events and 
identify protease substrates. Considering the functional relevance of proteases for all 
living processes, and the fact that many infectious microorganisms, viruses and 
parasites use proteases as virulence factors, there has been an increasing interest in 
developing protease research. In the past years, a new field emerged with the name 
‘degradomics’, described as all genomic and proteomic approaches for the 
identification and characterization of proteases present in an organism, including the 
substrates that are targeted by these proteases and their endogenous inhibitors. The 
complete natural substrate repertoire of a protease in a cell, tissue or organism is then 
called ‘degradome’ (Lopez-Otin and Overall, 2002). 
A conventional gel-based proteomic method is the two dimension gel electrophoresis 
(2D-PAGE), which can be used for comparison and relative quantification of various 
proteome states (Issaq and Veenstra, 2008). This technique separates proteins 
according to two independent proprieties in two discrete steps. The first dimension 
step, isoelectric focusing, separates proteins according to their isoelectric points; the 
second dimension step, sodium dodecyl sulfate-polyacrylamide gel eletrophoresis 
(SDS-PAGE), separates proteins according to their molecular weight. As result, each 
spot on the gel corresponds to a single protein species in the sample. The coupling of 
this method with mass spectrometry allows the identification of proteins. Despite 
alternative technologies that have emerged, 2D-gel is currently the only technique 
that can routinely separate up to thousands of proteins in complex protein mixtures.  
Furthermore, it delivers a map of intact proteins that reflects changes in protein 
expression level, post-translation modifications, and isoforms. When first used, this 
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approach enabled the discovery of protease substrates (Hwang et al., 2004). Using 
this method indeed, the protease is able to interact with its substrates in their native, 
folded conformations, mimicking the interaction of enzyme and substrate in vivo. 
Natural substrates are then cleaved by the protease, while remaining intact in a 
control sample not treated with protease. To determine which of the many proteins 
in the complex mixture were cleaved by the protease, the 2D protein profiles of 
control and protease-treated samples are compared. Protein spots that are in greater 
abundance in the control sample than the protease-treated sample are candidate 
substrates that underwent cleavage. On the other hand, spots that are in greater 
abundance in the protease-treated sample are potential cleavage products generated 
by the protease (Fig. 1). 
2D-gel methods have been applied to caspase substrate identification, revealing 41, 
13, and 15 putative substrates of caspase-1, caspase-3, and caspase-7, respectively 
(Agard and Wells, 2009). Similarly, the degradome of the bacterial protease Isp-1 (Lee 
et al., 2004) was examined and substrates of the matrix metalloprotease-14 have been 
identified in human plasma (Hwang et al., 2004). Moreover, its application for 
proteome mapping contributed to identify novel proteins involved in specific cellular 
pathways or compartments. The Proteome 2D-PAGE Database is a database for 
storing 2D-gel maps of a broad range of organisms, from human to microorganisms 
(http://web.mpiib-berlin.mpg.de/cgi-bin/pdbs/2d-page/extern/index.cgi). 2D-
PAGE maps of M. tuberculosis H37Rv culture filtrate and lysate proteins have been 
established, as well as the maps of the cellular proteins of M. bovis BCG substrain 
Copenhagen and Chicago. 231 and 138 different M. tuberculosis ORFs have been 
identified in 2D-PAGE maps of the cellular proteins and culture supernatant 
proteins, respectively.  
Due to its large and successful application in protease substrate identification, the 
2D-PAGE coupled to mass spectrometry was employed to identify Zmp1 substrates. 
The main goal of this study was to identify putative endogenous substrates of the 
zinc metallopeptidase Zmp1. Although Zmp1 was found in M. tuberculosis 
supernatant (Master et al., 2008), in this study the protein was detected uniquely in 
the cell pellet. Hence, the 2D-PAGE maps of the proteome of BCG WT and the 
mutant BCG ∆zmp1 were compared. Moreover, a comparative analysis of the 
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proteome of BCG ∆zmp1 incubated in presence or absence of purified active Zmp1 
was performed. In both approaches, the protein profiles were investigated and the 
differences in the spot intensity were analysed. 
             
    
    
Fig.1 Scheme of 2D-PAGE applied for protease substrate identification. The circled spot (top) shows a 
decreased intensity in the protein profile of the treated sample, indicating cleavage event on that 
protein. Conversely, substrates may be identified by detection of their cleavage products, which 
appear as new spot in the treated sample (bottom). Both full-length proteins and cleavage products 
can be picked and identified by MS (Bredemeyer et al., 2005). 
 
EXPERIMENTAL PROCEDURES 
Bacterial strains and protein extraction 
M. bovis BCG Pasteur WT and M. bovis BCG Pasteur ∆zmp1 (Master et al., 2008) were 
cultured in 7H9 medium or Sauton’s medium at 37° C, cells were harvested by 
centrifugation in late exponential phase (3 weeks). For preparation of the lysate, 
bacteria were washed twice in PBS, pH 7.4. The bacterial pellet was resuspended in 
PBS, and sonicated for 15 min at 4°C in the sonication bath (Transsonic 460, Elma). 
The total protein extract resulted from the supernatant recovered after centrifugation 
of the homogenates at 16000 g for 20 min at 4° C. The protein concentration was 
determined by BCA protein assay (bicinchoninic acid).  
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Western blot analysis 
50 µg of total protein extracts and 1-2 ml of precipitated culture supernatant were 
loaded on SDS-PAGE (12.5 % Tris-HCl gels, BioRad) and immunoblotted on a PVDF 
membrane (BioRad) by a semi dry apparatus (BioRad). The membranes were 
incubated in antibody solutions against Zmp1 (1:2500), KatG (1:5000) and Antigen85 
(1:2500). A second antibody coupled with HRP (horseradish peroxidase, 1:20000, 
Invitrogen) was used to visualise the first antibody. Zmp1 antibody was a gift from V. 
Deretic.  
Proteolytic digestion with the zinc metallopeptidase Zmp1 
The zinc metallopeptidase Zmp1 was purified as described in Petrera et al., 2012. The 
peptidase was stored at – 80° C in aliquots of 1 mg/ml. A proteolytic digestion was 
set up in a  final volume of 1 ml. 600 µg of protein extract were incubated with 30 µg 
of Zmp1 in the reaction buffer (100 mM TRIS pH 7.3, 100 mM NaCl, 0.05% BriJ) for 
1h at 37° C. A parallel reaction with inactive Zmp1 (heat-inactivated at 80° C for 20 
min) occurred. Zmp1 activity before and after proteolytic reaction was assessed with 
a fluorogenic substrate, as described in Petrera et al., 2012. After reaction, protein was 
precipitated with TCA-acetone. 13% ice cold acetone was added and the mixture was 
incubated for 2 h at 4° C.  Precipitated protein was collected by centrifugation (16000 
g, 20 min, 4° C), washed with one volume of 100% ice cold acetone, and dried by 
vacuum concentrator (Concentrator 5306, Eppendorf) for 5 min at RT.   
Two-dimensional gel electrophoresis Isoelectric Focusing (IEF) 
For isolectric focusing (IEF), rehydration buffer (7M Urea, 2M Thiourea, 2% CHAPS, 
50 mM DTT, 2% Pharmalyte, 0.123% TBP) was added to the protein pellet. The 
resuspended protein mixture was split  for running three parallel gels (200 µg/gel). 
24 cm immobilized pH gradient (IPG) strips (Bio-Rad) of pH range 4-7 were 
rehydrated overnight at 20° C with 450 µl of sample containing protein (200 µg). IEF 
was performed in a  IEF cell (Bio-Rad) using the following six-step program: a) 0-150 
V, 3 h; b) 300 V constant for 3 h; c) 1000 V, 5 h; d) 8000 V, 3 h; e) 8000 V constant for 9 
h;  f) 500 V constant for minimum 1 h. The current limit was set at 50 µA/strip. 
SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
After IEF, each strip was equilibrated for 15 min in a solution containing 0.05 M Tris-
HCl, pH 8.8, 6 M urea, 30 % glycerol, 2 % SDS, 130 mM DTT followed by a second 
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bath with the same solution but containing 135 mM iodoacetamide in place of DTT. 
Each IPG strip was placed on top of a vertical SDS-polyacrylamide gel (12.5% 
polyacrylamide concentration) and sealed in place with 0.5 % low melting agarose 
dissolved in running buffer (25 mM Tris-HCl, pH 8.3, 192 mM glycine, 0.1 % SDS) 
containing 0.002 % bromophenol blue. Molecular mass markers (Bio-Rad) were 
loaded in a separate well by the side of the strip. SDS-PAGE was performed in Ettan 
Dalt II system (Amersham Biosciences) with three-step program: a) 2 W/gel for 45 
min; b) 17 W/gel for 4 h; c) 1 W/gel as a hold. After electrophoresis gels were stained 
with SYPRO Ruby and photographed. 
In-gel digestion and MS analysis 
The spot intensity and the intensity ratio WT/mutant were calculated with the 
programs ProteomWeaver and Progenesis SameSpots. Stained spots were excised 
from the gel, washed with 100 mM ammonium bicarbonate, dehydrated with 
acetonitrile (80% solution) for 10 min and dried in a vacuum concentrator for 5 min. 
The proteins were then digested with trypsin (Promega) for 3-6 h at 37° C. The 
tryptic peptides were prepared for MALDI-TOF analysis by concentration and 
desalting using ZipTip C18 (Millipore). They were eluted with saturated α-cyano-4-
hydroxy cinnamic acid solution in 50 % acetonitrile, 0.1 % TFA, and 0.7 µl of the 
sample were applied to the steel target plate and analysed by MALDI-TOF/MS and 
MALDI-MS/MS. The obtained mass spectra were searched against the M.tuberculosis 
complex database using MASCOT (http://www.matrixscience.com). 
 
RESULTS 
Study of localization of Zmp1  
The question about the secretion of Zmp1 was previously answered by Master and 
colleagues (Master et al., 2008). The protein was mainly found intracellularly and in 
minor amount in the supernatant of M. tuberculosis (Fig.2A). The abundant 
intracellular localization of Zmp1 in BCG WT was confirmed in this study. As shown 
in Figure 2B, Zmp1 was only detected in cell pellet of BCG WT, but not in the 
supernatant. Therefore, the bacterial proteome could contain Zmp1 substrates. 
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Fig. 2 A. Immunoblot analysis of Zmp1 in M. tuberculosis H37Rv in culture supernatants and cell pellet 
(Master et al., 2008). Culture filtrate protein (CFP) and cell pellet were subjected to Western blotting 
and probed against antibodies specific for Zmp1 and KatG. The mycobacterial cytoplasmic enzyme 
KatG was probed for assessing nonspecific lysis in the CFP fraction. B. Immunoblot analysis of Zmp1 
in M. bovis BCG WT in culture filtrate and cell pellet. The secreted mycobacterial Antigen85 was 
probed for assessing the preparation of supernatant proteins. 
 
Analysis and comparison of 2D-gel profiles of M. bovis BCG WT and M. bovis 
BCG ∆zmp1 
A first approach dealt with the comparison of the proteome of BCG WT and BCG 
∆zmp1, searching for modification in the mycobacterial protein pattern due to the 
presence of the zinc metallopeptidase Zmp1. 600 µg of total protein extract were 
precipitated with TCA/acetone. The protein pellet was suspended in appropriate 
volume of 2D rehydration buffer and then split for running three parallel gels. 
Finally it was subjected to first-dimensional isoelectric focusing and second-
dimension SDS-PAGE. The pH range 4-7 was selected as the majority of proteins 
have a pI within that range, permitting therefore to zoom into this region. The use of 
the immobilized pH gradient (IPG) technology offered significant advantage in terms 
of resolution and reproducibility. The original method for first-dimension IEF was 
based on carrier-ampholyte-generated pH gradient in cylindrical polyacrylamide 
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gels cast in glass rods or tubes. As a result of limitations and problems associated 
with carrier ampholyte pH gradients, an immobilized pH gradient was developed, 
by covalently incorporating a gradient of acidic and basic buffering groups 
(immobilines) into a polyacrylamide gel at the time it is cast. For the second 
dimension, 12.5 % polyacrylamide concentrated SDS-gel was chosen to detect 
proteins in the broad range 15-100 kDa. The 2D-gels of wild-type and mutant show a 
very similar protein pattern (Fig. 3). The intensity of the spots was quantified and 32 
spots have been picked as recording an intensity ratio WT/mutant above 1.5 or 
below 0.6. 21 out of them were identified by MS analysis. The identified spots are 
listed in Table 1. The functional analysis of the hits revealed that the majority of the 
proteins are metabolic enzymes, involved in diverse cellular processes. The 
overrepresentation of this class of enzymes can be explained considering the two 
different genetic backgrounds here compared. The lack of the zinc metallopeptidase 
Zmp1 might influence the cellular metabolism and indirectly perturb some biological 
pathways. Therefore in two different genetic backgrounds some enzymes can be 
differently expressed. Although it is clearly interesting to study the modification of 
the protein expression pattern upon depletion of Zmp1, the subject of this study was 
focused on the identification of its substrates. The spot recording the highest ratio 
WT/mutant was identified as the conserved hypothetical protein Hrp1, hypoxic 
response protein 1, encoded by the M. tuberculosis gene Rv2626c (MW=15.5 kDa). The 
spot appears 3.7 fold more intense in the WT sample, i.e. in presence of Zmp1, 
suggesting that it is a cleavage product of the protein Hrp1. As the molecular mass of 
the spot corresponds approximately to the full size protein, it could be envisaged a 
partial C- or N-terminal digestion of Hrp1 by Zmp1. The second highest hit is the 
putative uncharacterized protein Rv1680. No information is available about this 
protein, although the large size (274 amino acids) decreases the chances of being 
cleaved by Zmp1, which shows a clear preference for small proteins (Ferraris et al., 
2011).  
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Fig.3 2D-PAGE analysis of BCG WT and BCG ∆zmp1. Mycobacterial lysates were prepared from 
cultured strains. The proteins were separated on 2D gel, and then SYPRO Ruby-stained for 
visualization of protein spots. (top) 2D-map of BCG ∆zmp1; (bottom) 2D-map of BCG WT. Here 
represented one of the three gels run for each strain. 
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 Proteins overrepresented in WT Fold WT/mutant 
1 Hypoxic response protein 1 Rv2626c  3.7 
2 Putative uncharacterized protein Rv1680 2.6 
3 Enoyl-[acyl-carrier-protein] reductase [NADH] inhA  2.5 
4 Uncharacterized protein Mb1315 (Carbonic_anhydrase) 2.3 
5 Putative uncharacterized protein Rv0801 (Glyoxalase Family) 2.2 
6 Bacterioferritin A Mb1907 2.1 
7 Beta 1,3-Glucanase Rv0315 2 
8 Divalent cation-transport integral membrane protein mntH     2 
9 Enolase Mb1051 2 
10 Riboflavin synthase alpha chain  ribE 1.9 
11 ATP-dependent Clp protease proteolytic subunit 1 1.8 
12 PhosphatidylEthanolamine-Binding Protein   Mb2164c  1.7 
 Proteins underrepresented in WT  
13 Isocitrate lyase Mb0476 0.28 
14 Fatty acid desaturase MT0846 0.32 
15 Possible dioxygenase   Mb3186c 0.32 
16 DNA-binding response regulator mtrA 0.43 
17 Probable glutamine synthetase 2 Mb2246c 0.43 
18 Elongation factor Tu 0.5 
19 Succinyl-CoA synthetase beta chain 0.52 
20 Uncharacterized protein (stress protein UspA)  0.52 
21 Glutamine synthetase 1 glnA1 0.6 
 
Table 1. List of identified proteins which recorded a significant intensity ratio between WT and 
mutant. The spot intensity ratio was calculated by the program ProteomWeaver. The values result 
from the analysis of three parallel gels.  
 
Analysis and comparison of 2D-gel profiles of M. bovis BCG ∆zmp1 incubated 
with  Zmp1 
The disadvantage of dealing with two different backgrounds, inevitably introducing 
variations in protein expression pattern, was overcome by comparing the same 
bacterial proteome treated or untreated with purified active Zmp1. The 
mycobacterial proteins were extracted from BCG ∆zmp1, in order to arrange a 
complete set of proteins not affected by Zmp1 activity. 600 µg of protein extract were 
incubated with 30 µg of active or heat-inactivated Zmp1 in the reaction buffer (see 
Experimental procedures) for 1 h at 37° C. The protein mixture was then precipitated, 
the pellet was resuspended in rehydration buffer and the volume was split for 
running three parallel gels. Comparison of 2D gel patterns of mycobacterial proteins 
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treated with active or inactivated Zmp1 demonstrated that Zmp1 treatment did not 
cause nonspecific, overall degradation of bacterial intracellular proteins. Instead, 
specifically six spots showed a decreased or increased intensity upon Zmp1 
treatment (Fig.4). Three spots out of six were identified by MS analysis. Spot 1 is the 
riboflavin synthase alpha chain (intensity ratio WT/mutant = 2.1). Spot 4 is the 
bacterioferritin A (intensity ratio WT/mutant = 1.9). Both proteins were identified in 
the previous experiment (hits num. 10 and 6, respectively). The spot 6 is the protein 
Rv2626c (intensity ratio WT/mutant = 3). The spot appears also in this experiment 
more pronounced in presence of Zmp1 (Fig. 5A and 5B). To confirm Rv2626c as a 
substrate of Zmp1, the experiment was repeated. As shown in the Fig.5C, the result 
was reproduced. Two out of three spots have still decreased intensity in the control 
gels. 
 
 
 
 
 
 81
 
 
Fig.4 2D-PAGE analysis of M. bovis BCG ∆zmp1 proteome incubated with Zmp1 for 1 h at 37° C. The 
proteome derives from the mutant strain M. bovis BCG ∆zmp1, which after treatment with active and 
heat-inactivated Zmp1 was loaded in 2D-gel. The gel was stained with SYPRO Ruby for visualization 
of protein spots. (top) 2D-map of M. bovis BCG ∆zmp1 untreated proteome; (bottom) 2D-map of M. 
bovis BCG ∆zmp1 proteome treated with Zmp1. Here represented one of the three gels run for each 
condition. 
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Fig.5 Spot of the protein Rv2626c. (A) The spot in the comparative analysis of the wild-type and 
mutant proteomes. (B,C) The spot in the 2D-gel of the mutant proteome incubated with Zmp1 in the 
first (B) and in the second trial (C).  
 
DISCUSSION 
The search of Zmp1 substrates was approached by the application of proteomic tools. 
The method considered the most suitable for the aim of the study was the 2D-PAGE, 
as it turned out to be very fruitful in the investigation of several eukaryotic and 
prokaryotic protease substrates. This study started questioning which proteome is 
targeted by Zmp1: the mycobacterial proteome or the host cell proteome. The 
abundance of intracellular Zmp1 led to consider the hypothesis that it cleaves 
endogenous substrates. First, the proteome of BCG WT and Zmp1-mutant were 
compared by 2D-gel analysis. 21 spots recording an intensity ratio WT/mutant above 
1.5 or below 0.6 have been identified. As expected by comparing different 
backgrounds, most of the hits corresponded to metabolic enzymes and housekeeping 
proteins. One hit, the product of the M. tuberculosis gene Rv2626c, was noteworthy 
for two reasons. First, it recorded the highest ratio WT/mutant in the assay and 
second, its biological function is closely correlated to mycobacterial virulence. The 
gene encodes for the hypoxic response protein 1 (Hrp1), a highly expressed member 
of the dormancy survival regulon DosR, and therefore involved in M. tuberculosis 
persistence. The protein is secreted from the bacterium in hypoxic in vitro culture 
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(Sharpe et al., 2008). The small conserved protein (143 amino acids) activates 
macrophages by significant induction of pro-inflammatory cytokines (Bashir et al., 
2010). It is reasonable to assume that M. tuberculosis takes advantages from its 
degradation by the zinc metallopeptidase Zmp1 to dampen the host immune 
responses.  
In order to reduce the variations derived by comparing two different genetic 
backgrounds, the proteome of BCG ∆zmp1 was analyzed upon treatment with 
Zmp1. Only few spots showed a significant difference in intensity, demonstrating an 
absence of unspecific cleavage. The identified proteins were metabolic enzymes 
already found in the previous approach, and Rv2626c. In both approaches the 
protein spot Rv2626c appeared more intense in presence of Zmp1, and it recorded 
the highest ratio among the hits. The higher intensity of the spot in presence of the 
peptidase suggests that it could represent a cleavage product of the protein Rv2626c. 
Ideally, the 2D-gel analysis allows to detect the cleavage product and the 
corresponding full-length substrate on the same gel, as a proof of the proteolytic 
event. In the experiments described here, the full-length substrate was not detected 
in the control gel.  
A major limitation of the 2D-PAGE is the inability to resolve extremely acidic, basic 
or hydrophobic proteins such as membrane-bound proteins, and also smaller 
proteins and peptides (<15 kDa). In addition, low abundance proteins are excluded 
as well, resulting overall in limited proteome coverage.  
The 2D-PAGE technique, despite its limitations, provided an interesting clue in the 
study of endogenous substrates of Zmp1. The protein Rv2626c represents a putative 
Zmp1 substrate, and further investigation can corroborate this hypothesis. Moreover, 
considering the low proteome coverage of the method, other putative endogenous 
substrates might be envisaged. For instance, the small sized proteins have been 
excluded by the analysis, and they represent a likely target for Zmp1.  Whether 
Zmp1 targets substrates within the host cell has to be investigated. As shown by 
Master and colleagues, Zmp1 might exert its activity out of the bacterial cell, within 
the phagosome environment or in the cytosol. Therefore the macrophage phagosome 
needs to be tested for searching Zmp1 proteolytic events. For such purpose, an 
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advanced proteomic techniques would be more suitable, such as mass spectrometry-
based global proteome analysis. 
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Abstract 
Zinc metallopeptidases of bacterial pathogens are widely distributed virulence 
factors and represent promising pharmacological targets. In this work we have 
characterized Zmp1, a zinc metallopeptidase identified as a virulence factor of 
Mycobacterium tuberculosis and belonging to the neprilysin (M13) family,  whose 
X-ray structure has been recently solved. Interestingly, this enzyme shows an 
optimum activity toward a fluorogenic substrate at moderately acidic pH values 
(i.e., 6.3), which corresponds to those reported for the Mtb phagosome where 
this enzyme should exert its pathological activity. Substrate specificity of Zmp1 
was investigated by screening a peptide library. Several sequences derived from 
biologically relevant proteins were identified as possible substrates, including the 
neuropeptides bradykinin, neurotensin and neuropeptide FF. Further, 
subsequences of other small bioactive peptides were found among most 
frequently cleaved sites, e.g. apelin-13 and substance P. We determined the 
specific cleavage site within neuropeptides by mass spectrometry, observing that 
hydrophobic amino acids, mainly phenylalanine and isoleucine, are 
overrepresented at position P1’. In addition, the enzymatic mechanism of Zmp1 
toward these neuropeptides has been characterized, displaying some differences 
with respect to the synthetic fluorogenic substrate, and indicating that the enzyme 
adapts its enzymatic action to different substrates. 
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Introduction 
Tuberculosis (TB), the major cause of mortality around the world, kills about 
two million people annually, and approximately one-third of the world’s 
population is asymptomatically infected with Mycobacterium  tuberculosis, the 
main causative agent of the disease (WHO Fact sheet; http://www.who.int/ 
mediacentre/factsheets/fs104/en/index.html). The prolonged coevolution of M. 
tuberculosis with its human hosts, and specifically with macrophages, has turned 
out in a peculiar survival strategy. Unlike other bacteria, which have developed 
different strategies, pathogenic mycobacteria (Mtb) have evolved to block 
lysosomal delivery (Nguyen and Pieters, 2005; Warner and Mizrahi, 2007). Hence, 
the pathogenic Mtb strategy demands that it actively subverts normal cellular 
mechanisms to avoid being killed (Nguyen and Pieters, 2005; Masjedi et al., 2006). 
The Rv0198c gene of Mtb encodes for the zinc metallopeptidase 1 (Zmp1) (663 
aa), which, although not required for mycobacterial growth per se, turned out to 
be essential for survival inside host macrophages (Master et al., 2008). An 
equivalent peptidase gene is also conserved in Mycobacterium leprae 
(MLCL622.12c;  667 aa), the causative agent of leprosy, whose genome  exhibits  
massive  gene  decay  (Cole  et  al.,  2001). Master and colleagues have described 
Zmp1 as a secreted virulence factor of M. tuberculosis, involved in phagosome 
maturation arrest. Zmp1 manipulates host immune defence by interfering with 
the activation of a multiprotein complex termed inflammasome (Master et al., 
2008). Furthermore, zmp1  deletion influences the presentation of mycobacterial 
antigens, thus increasing the immunogenicity of BCG (Johansen et al., 2011). The 
important role of Zmp1 in the Mtb pathogenicity has been recently confirmed in 
a mice model (Muttucumaru et al., 2011), even though some questioning about the 
mechanism remains open.  
Zmp1 belongs phylogenetically to the MEROPS peptidase family M13 and 
displays the conserved HExxH active site motif common to all Zn2+ 
metallopeptidases. The targets of M13 members usually are bioactive peptides with 
a key function in the regulation of cardiovascular, nervous and immune systems 
(Turner et al., 2001). Zmp1 shares particularly primary sequence similarity (48%) 
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with human neprilysin (749 aa), an extracellular peptidase that preferentially 
hydrolyzes extracellular oligopeptides (<5 kDa) on the amino side of hydrophobic 
residues (also including amyloid beta peptides implicated in Alzheimer’s disease) 
(Carson and Turner, 2002; Madani et al., 2006). We recently solved the crystal 
structure of Zmp1 and our investigation demonstrated that Zmp1 and 
neprilysin are also structurally conserved (Ferraris et al., 2011). A major aspect 
concerns the active site of Zmp1, which is accessible only through a narrow 
channel, rendering difficult the interaction with large macromolecular substrates;  
therefore, the enzyme seems more tailored to process peptides.  Here we report the 
characterization of the proteolytic activity of Zmp1 metallopeptidase, describing its 
substrate preferences, by employing a microarray based peptide library and 
analyzing its cleavage specificity by mass spectrometry. In addition, we have  
investigated the pH effect on Zmp1 catalysis, revealing an optimum activity at 
moderately acidic pH values which are substrate-dependent. 
 
Results 
Zmp1 activity depends on Zn
2+ 
binding 
M. tuberculosis  zmp1  was  cloned  into  a  prokaryotic  expression  vector  carrying  
a  His6 modification at its N-terminus and HA tag at its C-terminus for purification 
and detection. In addition, GST-zmp1-His/HA tagged protein was cloned. Both 
proteins were expressed to high levels in E. coli and purified in a two step 
approach using HisTrap column and ion exchange/GST-sepharose beads. Purity 
was > 95% according to a single band at the expected molecular weight in the SDS-
PAGE (Figure 1A). Two mutants in the HExxH signature motif were produced by 
site-directed mutagenesis, namely H493A (His493 was altered to Ala) and E494A 
mutant (Glu494 was altered to Ala). Both mutated proteins were produced in a 
stable and soluble form and were purified to a high degree (Figures 1A and 1B). 
In order to complement the crystallography data with the study of the protein 
in solution, circular dichroism spectroscopy was applied to Zmp1. In accord with 
the crystal structure (Ferraris et al., 2011) all purified forms of Zmp1 (i.e., wild 
type and the mutant) are properly folded, displaying identical CD spectra (Figure 
1C). As predicted from the primary amino acid sequence and in agreement with 
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the crystal structure (Ferraris et al., 2011), the secondary structure of Zmp1 
displays over 70% of an α-helix structure, as estimated from the  molar ellipticity 
at 222 nm (Morrow et al., 2000). Salts, such as CaCl2 and NaCl, do not alter the 
thermal stability of Zmp1 helical folding (data not shown). Zmp1 is able to cleave 
a synthetic fluorogenic substrate (see the materials and methods section), which 
is specific for a family of zinc endoproteinases, called matrix metalloproteinases 
(MMPs), sharing the catalytic motif (i.e., HExxH) with the M13 family. GST-
Zmp1 wt cleaved the fluorogenic substrate with high efficiency and, as expected, 
mutating the catalytic motif almost abolished the proteolytic activity. Likewise, 
EDTA and the Zn2+ chelator 1,10-phenanthroline reduced Zmp1 activity (see 
Table 1). Zmp1 activity was also strongly inhibited by the potent M13 
metallopeptidases inhibitor phosphoramidon with a KI= 3.5(±0.5)×10-8 M (Ferraris 
et al., 2011). The enzyme does not undergo auto- proteolysis during the activity 
assay, as proved by the Selwyn's test (Selwyn, 1965) (see Figure S1). 
 
Table 1 Effect of peptidase inhibitors on the activity of Zmp1. 
 
 
Inhibitor Concentration (mM) Zmp1 activity (% of control) 
Phosphoramidon 0.1 5.1 ± 1.2 
1,10-Phenanthroline 0.1 7.8 ± 3.2 
EDTA 1 46.4 ± 8.3 
 
Zmp1 (10 nM) was preincubated with inhibitor for 10 min or 60 min (in case of 
EDTA) at room temperature. Activity toward the synthetic fluorogenic substrate 
was measured after 5 min at 37°C (±SD). 
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Figure 1 Purification of Zmp1 and its structure in solution. 
Coomassie stain of 12.5% SDS-Gel (A) and Western blotting (B) of Zmp1 variants. 
Lane 1: Zmp1 wt; Lane 2: GST-Zmp1; Lane 3: GST-Zmp1 E494A; Lane 4: GST-
Zmp1 H493A. Zmp1 shows the predicted molecular mass of 72 kDa. The three 
GST-tagged variants have a molecular mass of approximately 100 kDa due to the 
fusion with a 26 kDa GST-tag. (C) Circular dichroism spectra of Zmp1.  Dashed 
line corresponds to the circular dichroism spectrum of the wild type Zmp1, 
continuous line refers to the inactive E394A Zmp1. 
 
pH dependence of Zmp1 proteolytic activity 
The pH dependence of Zmp1 activity has been first measured employing a 
synthetic fluorogenic substrate. From the analysis of the dependence on the 
substrate concentration at each pH value according to Eqs (2) and (3) (see 
Materials and Methods) we have obtained the catalytic parameters (i.e., kcat/Km, 
kcat and Km) at each investigated pH. Their pH dependence is reported in Figures 
2A-2C for kcat/Km (panel A), kcat (panel B) and Km (panel C), respectively, 
obtaining the pKa values reported in Table 2. Although the non-linear least- 
squares fitting of the pH dependence of individual parameters might have been  
carried out with only two protonatable groups, the global fitting of the pH 
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dependence of all three catalytic parameters demanded three  protonatable  
groups  [i.e., n = 3  in  Eqs (4a-c), see materials and methods]. Evidently, the 
overall enzymatic activity of Zmp1 (corresponding to kcat/Km) is highest at  pH 
6.3 (Figure  2A), a pH value quite low compared to other metallopeptidases 
(Fasciglione et al., 2000). Further, the pH dependence of Km (Figure 2C) indeed 
suggests that the substrate affinity tends to increase at pH lower than 7.5, since 
Km decreases. An interesting pattern is observed for the pH dependence of kcat 
(Figure 2B), where it appears evident that at least two groups with markedly 
different pKa values are modulating this parameter. In particular, it is worth 
underlining that the two-protonated species appears the  most active form of 
Zmp1 and that this enhanced activity is connected to a residue characterized by 
a pKa = 6.73±0.17 in the free enzyme, which then shifts to a pKa = 7.72±0.16 in the 
substrate-bound form (Table 2).  As a consequence, the pH-dependent profile of 
kcat appears somewhat displaced toward higher pH values. 
Table 2 Catalytic parameters for the different protonated species of Zmp1 
toward the synthetic fluorogenic substrate and pKa values for the protonating 
groups in the free enzyme (pKU) and of the substrate-bound enzyme (pKL). 
 
 
 kcat/Km (M
-1 s-1) kcat (s
-1) Km (M) 
0-protonated 5.0(±0.7) × 103 0.012±0.004 2.4(±0.4) × 10-6 
1-protonated 7.1(±0.9) × 103 0.131±0.029 1.9(±0.3) × 10-5 
2-protonated 3.0(±0.5) × 104 0.065±0.017 2.2(±0.5) × 10-6 
3-protonated 9.5(±1.6) × 102 0.008±0.001 8.4(±1.6) × 10-6 
 
pKU1 8.17±0.16  
pKU2 6.73±0.17 
pKU3 5.43±0.19 
pKL1 7.22±0.18 
pKL2 7.72±0.17 
pKL3 5.69±0.18 
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Figure 2 pH dependence of catalytic parameters for Zmp1 at 37°C against a 
synthetic fluorogenic substrate. (A) pH dependence of kcat/Km. Continuous line 
represents the non-linear least squares fitting of data employing Eq. (4a) with 
parameters reported in Table 2. (B) pH dependence of kcat. Continuous line 
represents the non-linear least squares fitting of data employing Eq. (4b) with 
parameters reported in Table 2. (C) pH dependence of Km. Continuous line 
represents the non- linear least squares fitting of data employing Eq. (4c) with 
parameters reported in Table 2. (D) Ilomastat concentration dependence of 
substrate affinity constant Km for Zmp1 at 37°C. Values of 
obsKm have been 
obtained by Lineweaver-Burk plot of omni-MMPs fluorogenic peptide cleavage 
in the presence of Zmp1 (0.4 nM) in absence and presence of different Ilomastat 
concentrations (namely 5, 10, 15, 30 and 60 µM). The continuous line is the non- 
linear least-squares fitting of data according to Eq. (5), from which a value of     
0Km = 4.4(±0.6) × 10
-6 M and a value of KI = 5.9(±0.7) × 10-5 are obtained. 
 
 93
Zmp1 inhibition by Ilomastat 
The inhibition constant by Ilomastat has been determined for Zmp1, exploiting 
the inhibitor concentration dependence of the substrate affinity (Figure 2D). 
Application of Eq. (5) (see Materials and Methods) allows to determine the KI       
[= 5.9(±0.7)×10-5 M], that is a value about 105-fold higher than that observed for 
matrix  metallopeptidases  (Galardy  et  al.,  1994), reflecting a very low affinity of 
Ilomastat for Zmp1. This result indicates that Ilomastat is a very weak  inhibitor 
for Zmp1, confirming the known difference between gluzincins and metzincins, 
as indeed it turns out to be evident also from the crystallographic structure, where 
the catalytic site results different from that of other metallopeptidases (Ferraris et 
al., 2011). 
Zmp1 hydrolyzes a variety of bioactive peptides 
In order to possibly identify the native substrate(s) of Zmp1 we carried out an 
extensive screening of a microarray based peptide library. The library consists of 
1989 octameric peptides derived from annotated cleavage sites of peptidases or 
random sequences and 1536 pentadecameric random peptide sequences. Peptides 
are C-terminally tagged with a phosphorylated tyrosine for detection. Peptide 
cleavage was quantified by incubation with anti-phosphotyrosine and fluorescent 
secondary antibody labeling and following fluorescence measurement. 
Fluorescence intensity of 51 out of 3525 peptide spots was decreased by more 
than 90% as compared to the BSA control. The 51 substrates were categorized into   
three groups (Table S1): 1) neuropeptides/substrates of NEP or ECE-1; 2) 
coagulation factors; 3) others. Interestingly, only short peptides (octameric) were 
represented among the top substrates. The relative frequency  of each amino acid 
in the efficiently cleaved peptides was calculated by dividing the number of times 
this specific amino acid is represented in the screened substrates over the number 
of times that the amino acid is represented in the whole peptide microarray. This 
statistical analysis provides information about the amino acid preferences in the 
substrates, even though it does not allow prediction of actual cleavage sites. The 
most common motif among the top substrates was the sequence SPFR, which is 
present in the carboxy terminal part of the peptide hormone bradykinin. In 
particular, the statistical analysis showed an overrepresentation of arginine, 
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phenylalanine, isoleucine, leucine and valine in the top substrate sequences,  
whereas acidic amino acids like aspartic or glutamic acid were 
underrepresented, and no cysteine or tryptophan were present in any of the 51 top 
substrates. 
Zmp1 cleavage motif 
Several cleavage motifs can be described from the MALDI-TOF cleavage 
analysis of the investigated peptides (Figure 3A). The phenylalanine was the most 
represented residue at P1’ position (Figure 3B), even though also isoleucine and 
leucine were abundant at this position. Proline was frequently found in the P3 
site,  although other positions near the cleavage site showed little preference. We 
conclude that PxxF is a preferred cleavage motif of Zmp1 and phenylalanine 
occupies P1’ position. 
Identification of substrate cleavage sites 
First, we characterized the cleavage pattern of several neuropeptides identified in 
the peptide array (i.e., bradykinin, apelin-13, neurotensin, neuropeptide FF), 
including some NEP or ECE-1 substrates (i.e., substance P, dynorphin A (1-13) 
and angiotensin I), and the reaction by-products were analyzed by  MALDI-TOF; 
in order to guarantee specific cleavage, high substrate/enzyme ratio was used 
(1000:1). Two  cleavage sites were detected in bradykinin (Figure 4A), i.e., 
between Pro7-Phe8 and Gly4-Phe5, confirming the results obtained with the 
extended  bradykinin, which is  generated by the proteolytic cleavage of the  
precursor kininogen-1 by the enzyme kallikrein (Kaplan et al., 2002). As a matter 
of fact, in rat, mouse, bovine and human the SPFR motif of kininogen-1 is 
conserved but it is followed by a different carboxy terminal amino acid. Four 
zinc metallopeptidases are mainly responsible for the metabolism of bradykinin, 
namely ACE, NEP, aminopeptidase P and carboxypeptidases M and N (Moreau 
et al., 2005). Both cleavages resulted in two respective fragments that were 
detected by  MALDI-TOF  (Figures  4B  and  4C). 
We determined three cleavage sites in substance P: between Gln6-Phe7, Phe7-Phe8 
and Gly9-Leu10 (Figure 4D). Interestingly, all the cleavage sites of bradykinin and 
substance P have a hydrophobic amino acid in the P1’ site, mainly  
phenylalanine, which is typical of neprilysin, ECE-1 and thermolysin; further, 
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this observation is in agreement with  the  overrepresentation of this amino acid in 
the top substrates as compared to the total peptide library. Specific sites of 
cleavage within the other neuropeptides, such as angiotensin I (Figure S3), 
apelin-13 (Figure S4), dynorphin A (1 – 13) (Figure S5), and neurotensin 
(Figure S6) are summarized in Figure 3A. 
 
 
 
Figure 3 Hydrolysis of hormone peptides by Zmp1. (A) Cleavage sites detected in 
the Zmp1 hydrolyzed fluorogenic peptides: 1) angiotensin I, 2) neurotensin, 3) 
apelin-13, 4) dynorphin A (1-13). Neuropeptide FF cleavage pattern was not 
studied because of poor detection signals in the MALDI-TOF analysis. (B) 
Amino acid preferences at various position of Zmp1  substrates calculated on the 
basis of the cleavage pattern of the studied hormone peptides. Size of amino 
acid letter is proportional to their occurrence  in  the  recognition/cleavage  motif.  
Cleavage site  (marked  with  red  arrow)  is localized between position P1 and P1’ 
(drawn using Weblogo 3.0). 
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Further, we synthesized a peptide fragment of mouse kininogen with the sequence 
RPPGFSPFRSVTV to map the cleavage site (bradykinin sequence in bold). The 
peptide was incubated with Zmp1 for 60 and 120 min, respectively, and products 
were analyzed by LC-MS. Cleavage sites were determined by calculating the 
molecular weight of putative products (data not shown). Primary cleavage 
occurred between Pro7 and Phe8 (Figure 4A, arrow with one star). This cleavage 
site lies within the bradykinin sequence and results in the inactivation of 
bradykinin rather than releasing bradykinin from its precursor. This peptide 
bond is also targeted by ACE, the main enzyme responsible for the metabolism of 
bradykinin (Blais et al., 2000). Further cleavages were detected after longer 
incubation of the peptide with Zmp1, e.g. between Gly4-Phe5 and Ser10-Val11 
(Figure 4A, arrows with two stars). 
Kinetic analysis of neuropeptides cleavage 
Zmp1 hydrolysis of the neuropeptides was further studied by the determination 
of kinetic constants Km and kcat. Since the kinetic course of peptide cleavage by 
Zmp1 was affected by (a) product inhibition and/or (b) cleavage of multiple 
peptide bonds, initial velocities were exploited for calculating the kinetic 
parameters of the most susceptible peptide bond within a given peptide. Results 
are summarized in Table 3 as best fit values with associated standard errors from 
non-linear regression of the Michaelis-Menten equation fitted to data. The kinetic 
parameters for angiotensin I and neurotensin could not be calculated because 
even the initial velocity was strongly affected by the concurrent multiple 
cleavage and multiple product inhibition. Figure 5A shows, as an example, the 
double reciprocal Lineweaver-Burk plot for substance P, apelin-13 and 
bradykinin; it clearly emerges that substance P and apelin-13 are the best 
substrates among those investigated. 
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Figure 4 Cleavage sites of bradykinin and substance P by Zmp1. (A) Determination 
of fragments of the ‘extended’ bradykinin (bradykinin sequence in bold) by 
Zmp1 through LC-MS analysis. Three different cleavage sites were detected in 
bradykinin. Primary site of hydrolysis is shown by the arrow with one asterisk, 
and secondary sites are shown by the arrows with two asterisks. (B)  MALDI-TOF 
spectrum of fluorogenic bradykinin. (C) MALDI-TOF spectrum of Zmp1 
hydrolyzed fluorogenic bradykinin. The C-terminal fragments showed an 
additional mass peak (∆16 Da), due to a loss of  oxygen (as described recently for 
nitro-phenyl-derivatives, see Petersson et al., 2001). (D) Cleavage sites of 
fluorogenic substance P by Zmp1. The arrows above the amino acid sequence of 
substance P indicate the cleavage sites. 
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Table 3 Kinetic parameters for the cleavage of the most susceptible peptide bond 
in five peptide substrates of Zmp1. 
 
 
Substrate kcat (s
-1) Km (µM) kcat/Km (M
-1s-1) 
Apelin 1.54 ± 0.08 1.09 ± 0.23 1.41 ± 0.31 × 106 
Substance P 4.78 ± 0.71 3.92 ± 1.37 1.22 ± 0.46 × 106 
Bradykinin 2.76 ± 0.42 7.99 ± 1.45 3.46 ± 0.67 × 105 
Dynorphin A 2.25 ± 0.22 5.72 ± 1.22 3.93 ± 0.92 × 105 
Neuropeptide FF 1.07 ± 0.16 3.02 ± 1.15 3.56 ± 1.45 × 105 
 
Values of kcat and Km, determined by non-linear regression from a fit of the 
Michaelis-Menten equation to primary data, are shown together with the standard errors 
from regression. 
 
pH dependence of substance P and apelin-13 hydrolysis 
In several studies ECE-1 was found to cleave neuropeptides inside acidified 
endosomes (i.e., at pH ≈ 5.5)  (Padilla  et  al.,  2007;  Roosterman  et  al.,  2007).  We 
determined the pH dependence of Zmp1 activity for additional substrates, i.e., 
apelin-13 and substance P in order to see the pH preference for these substrates.   
Zmp1 cleaved the two neuropeptides preferentially in the pH range between 6.5 
and 8.0 rather than at more acidic pH values, as observed for the MMP-2/MMP-
7 substrate (Figure 2 for the pH profile of the MMP-2/MMP-7 substrate, Figure 5B 
for that of substance P and apelin-13). Data obtained from the pH-dependence of 
apelin-13 and substance P degradation by Zmp1 are reported in Table 4. 
Screening for macromolecular substrates (longer than 40 amino acids) 
Employing an in vitro proteolysis assay we have investigated the enzymatic 
action of Zmp1 on four of the substrates reported on the top substrates list of 
the peptide array, namely (i) β-amyloid, (ii) α-fibrinogen chain, (iii) insulin and 
(iv) denatured collagen. We have further tested Zmp1 proteolytic activity on 
caspase 1, the IL-1β activating enzyme. However, even prolonged exposition to 
Zmp1 (up to 24 hours) did not lead to any appreciable cleavage of these 
potential substrates (data not shown). In contrast, a control incubation with trypsin 
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led to complete digestion of the α-, β- and γ-fibrinogen chains already after 1 h of 
incubation. 
 
Table 4 Values of kcat/Km (M-1s-1) for the different protonated species of Zmp1 
toward apelin-13 and substance P and pKa values for the protonating groups in 
the free enzyme (pKU). 
 
 
 Apelin-13 Substance P 
0-protonated 9.0(±1.6) × 105 8.8(±1.6) × 105 
1-protonated 1.7(±0.4) × 106 3.1(±0.7) × 106 
2-protonated 6.5(±1.1) × 105 1.6(±0.4) × 105 
3-protonated 1.0(±0.8) × 104 1.0(±0.7) × 105 
 
pKU1 8.17± 0.16  
pKU2 6.73±0.17 
pKU3 5.43±0.19 
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Figure 5 Kinetic analysis of Zmp1 hydrolysis of apelin-13, substance P and 
bradykinin. (A) Double-reciprocal Lineweaver-Burk plot of the enzymatic 
processing by Zmp1 of apelin-13 (o), substance P (x) and bradykinin (*) at 37°C 
and pH 7.3. Solid lines represent the non- linear least-squares fitting of data 
according to Eq. (2). (B) pH dependence of the rate of cleavage (kcat/Km) of 
apelin-13 (o) and substance P (x) by Zmp1 at 37°C. Continuous lines represent 
the non-linear least-squares fitting of data according to Eq. (4a). 
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Discussion 
Zinc metallopeptidases represent promising pharmacological targets and potential 
candidates for vaccine development (Miyoshi and Shinoda, 2000; Lopez-Otin and 
Bond, 2008; Baillie et al., 2010). We have investigated the wild type and the 
inactive mutants (H493A and E494A) of the metallopeptidase Zmp1, which is an   
important virulence factor of M. tuberculosis (Master et al., 2008). 
Zmp1 belongs to the M13 family (MEROPS database http://merops.sanger.ac.uk   
/), like neprilysin (NEP) and endothelin-converting enzyme-1 (ECE-1), whose 
enzymatic action is restricted to peptides with a strong preference for cleaving the 
amino terminal bond of hydrophobic residues (Bland et al., 2008). This preference 
for peptides is also confirmed by the recently solved X-ray crystallographic 
structure of Zmp1,  which reveals that the active site is located at the bottom of a 
hydrophobic channel, likely impairing the access of large macromolecular 
substrates in the proximity of the reaction centre (Ferraris et al., 2011). 
In order to better characterize the specificity of Zmp1 a peptide microarray 
library was employed (including octameric and pentadecameric peptides); in 
particular, octameric peptides were enzymatically cleaved with the highest 
efficiency; further, a statistical analysis over the whole peptide array indicates a 
marked tendency of Zmp1 to cleave bonds where hydrophobic amino acids are 
located at the P1’ position, similarly to NEP and ECE-1. In addition, as shown by 
the in vitro cleavage assay, sequences identified by the peptide array could not be 
cleaved when they were flanked by the whole protein sequences in a context of a 
structurally complex molecule (e.g. fibrinogen and β-amyloid). Among the hits 
screened several neuropeptides have been identified [i.e., substance P, neurotensin, 
bradykinin, apelin-13, angiotensin I, neuropeptide FF and dynorphin A (1-13)]. 
With respect to these, it is  interesting to remark that a member of M13 family 
(ECE-1) localizes into the luminal side of endosomal membrane where it degrades 
internalized neuropeptides (e.g., substance P and apelin-13) (Roosterman et al., 
2007; El Messari et al., 2004; Cottrell et al., 2009), suggesting their possible 
biological relevance as substrates of this type of enzymes. As a matter of fact, 
besides the classical involvement of neuropeptides in neurotransmission and  
vasal smooth muscle cells constriction, at least for some of them, a novel role in 
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the modulation of immune responses has been envisaged (Skidgel et al., 1984; 
Johnson et al., 1999; Marriott and Bost, 2001; Yaraee et al., 2007), affecting 
proinflammatory cytokine and chemokine activation (in the case of apelin-13) and 
macrophages activation (in the case of the substance P) in the early phases of 
immune responses to Salmonella infection (Kincy-Cain and Bost, 1996; O’ Connor et 
al., 2004; Leeper et al., 2009). 
A comparison between the degradation profile of these substrates by Zmp1, NEP 
and ECE-1 highlights overlapping specificities in terms of cleavage sites (i.e., for 
bradykinin, substance P and dynorphin A) with minor differences (i.e., secondary 
cleavage sites in angiotensin I and neurotensin) (Matsas et al., 1984; Johnson et al., 
1999). However, a significant quantitative difference in terms of catalytic efficiency 
with respect to ECE-1 is observed with kcat/Km ratios which in Zmp1 are 100- 
and 5-fold higher for substance P and bradykinin, respectively (Johnson et al., 
1999). On the whole, apelin-13 turns out to be an excellent substrate for Zmp1, 
being efficiently cleaved with the highest specificity constant (i.e., kcat/Km) 
among all tested peptides, a feature mostly related to the binding specificity 
rather than the cleavage efficiency. 
Even though we cannot state at this stage whether these neuropeptides represent 
the Zmp1 substrate in vivo, pH scanning of Zmp1 proteolytic activity toward all 
investigated peptides indicates that Zmp1 can modulate its activity through the 
dynamical pH changes which occur in the maturating phagosome. In this respect, 
it is noteworthy that degradation of neuropeptides by ECE-1 in endosomes under 
acidic conditions (i.e., pH 5.5) is documented and it is associated to intracellular 
signaling and receptor turnover (El Messari et al., 2004; Roostermann et al., 2007; 
Cottrell et al., 2009); analogously, we found that Zmp1 optimum of activity toward 
the synthetic substrate is at pH 6.3 (Figure 2A), a value corresponding to that of 
the early endosome (Pethe et al., 2004). Therefore, it might be speculated that, 
similarly ECE-1, Zmp1 operates within the phagosome, arresting its maturation 
(Johansen et al., 2011, Master et al., 2008). As a matter of fact, at the acid pH of the 
maturating phagosome (i.e., pH 6.3) the substrate affinity of Zmp1 is fairly high 
(i.e., 2 µM), suggesting a conformation of the active site particularly suitable to 
interact with substrates under quite acidic pH conditions. In the case of 
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neuropeptides, such as apelin-13 and substance P the optimum pH is somewhat 
higher than that observed for the synthetic substrate, although pKa values for the 
pH-dependence of kcat/Km are fully comparable. This strongly supports the idea 
that these pKa values refer only to the protonation of Zmp1 residues with no 
contribution from residues of the substrate(s). Therefore, since the whole 
enzymatic mechanism of Zmp1  seems to be modulated by the protonation of 
three classes of residues (characterized by pKa1, pKa2  and pKa3, respectively), the 
different pH profile between these substrates can be simply explained by the 
involvement of different protonated species (the 2-protonated for the synthetic 
substrate and the 1-protonated for neuropeptides). This feature is clearly 
reflecting a relevant difference between the two classes of substrates in their ionic 
interactions with the enzyme. 
These investigations demonstrate the importance of Zmp1 for mycobacteria host 
interaction and highlight its potential as a pharmacological target. Two major 
conclusions can be drawn, namely (i) Zmp1 preferentially  cleaves small peptides, 
among which neuropeptides appear particularly interesting; (ii) Zmp1 adapts its 
activity to different microenvironmental conditions. The present biochemical 
characterization of the enzymatic properties of Zmp1 can be merged with the 
structural information on Zmp1 (Ferraris et al., 2011), allowing to a structural-
functional correlation, which will be of the utmost importance for a rational 
drug design. 
 
Materials and methods 
Molecular cloning and protein expression 
M. tuberculosis zmp1 gene was subcloned into pET100/D-TOPO® vector 
(Invitrogen) using a PCR amplified product  from  pMV361-zmp1  vector,  carrying  
zmp1  gene,  as  previously reported (Master et al., 2008). For all constructs, 1 L 
overnight culture of E. coli BL21 (Invitrogen) in LB medium (induced at OD600  = 
0.8  with 0.5 mM IPTG and grown at 18°C) was centrifuged at 5000 g for 20 min, 
followed by washing with PBS and additional centrifugation at 5000 g for 20 min. 
Cells were then lysed by three French press cycles (Thermo Electron) at 1.4 × 108 
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Pa, in the presence of  peptidase inhibitors, followed by ultracentrifugation at 
30000 g for 60 min. Supernatants were loaded on HisTrap™ HP column (GE 
Healthcare) equilibrated with buffer containing 20 mM NaH2PO4  pH 7.4, 0.5 M 
NaCl. Proteins were eluted with a concentration gradient of imidazole. Both 
Zmp1 and GST-Zmp1 were eluted at 250 mM imidazole (protein concentration 
was 0.5-1 mg/ml). After overnight dialysis against PBS, Zmp1 wt was further 
purified by ion exchange using a Q Column (GE Healthcare). GST-Zmp1 
purification was performed using glutathione-sepharose beads (Glutathione 
Sepharose 4B, GE Healthcare). Proteins were dialyzed against PBS, and finally 
glycerol at a final concentration of 10% was added in order to store them in 
aliquots at -20°C. Proteins were analyzed by 12.5 % SDS-gel and subsequent 
Coomassie stain or Western Blot against HA. 
Circular dichroism experiments 
CD spectra for the validation of the correct folding of the protein were recorded 
on a Jasco J-710  spectropolarimeter equipped with a thermostated cell holder and 
connected to a data station for signal averaging and processing. All spectra were 
averages of four scans and were recorded employing quartz cells of 2-mm 
pathlength. Zmp1 was dissolved in CD buffer (20 mM Tris-HCl, 1 mM CaCl2, 
100mM NaCl) at about 2 µM concentration. The α-helix content of Zmp1 was 
calculated from the molar ellipticity of circular dichroic spectrum at  222 nm 
according to the following equation 
 
% α-helix = (-[θ]222nm +3000)/39000 (Equation 1)  
 
where [θ]222nm is the molar ellipticity at 222 nm, as previously described (Morrow 
et al., 2000).  
Kinetic analysis and pH dependence of Zmp1 catalysis 
Internally quenched fluorogenic substrates with 7-methoxycoumarin (MCA) as 
fluorophore and  2,4-dinitrophenol  (DNP)  as  quencher  were  either  a  synthetic  
fluorogenic substrate, displaying the following sequence: MCA[(7-
methoxycoumarin-4-yl)acetyl]-Pro-Leu-Gly-Leu-DNP[N-3-(2,4-dinitrophenyl)-L-
2,3-diaminopropionyl]-Ala-Arg-NH2) or neuropeptides from EMC microcollections  
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(Tübingen, Germany).  Neurotensin was synthesized with glutamine as N-terminal 
amino acid instead of pyroglutamic acid for ease of synthesis. The substrate 
peptides were prepared as stock solutions in 100% dimethyl sulfoxide (DMSO) at a 
final concentration of 1.0 mM and further diluted into the universal buffer (25 
mM Bis-Tris-HCl, 25 mM Tris-HCl, 100 mM NaCl and 10 mM CaCl2  prepared at 
25°C) so as to maintain unaltered the composition at different pH values over the 
range investigated, keeping the DMSO concentration constant at 1% (v/v) for all 
dilutions. Substrate hydrolysis was  measured  fluorometrically  with  an  Eclypse  
fluorimeter  (Varian)  or  with  a  Flx800 spectrofluorometer (BIOTEK) equipped 
with KC Junior Software (BIOTEK) (λexc  = 327 nm, λem = 393 nm); reactions were 
started by adding Zmp1 (at a final concentration of 10 nM) to a solution containing 
different substrates concentrations, spanning between 0.3 and 5 µM. For the pH 
dependence Zmp1 was incubated in the universal buffer between pH 5.2 and 9.5 
for 5 min at 37°C; then substrate was added and fluorescence signal was followed. 
Background fluorescence of all buffers was similar. The initial velocities were 
measured at 37°C within a time interval during which the rate was constant and 
less than 10% of the substrate has been degraded. It ensured a steady-state 
condition  and  it was a prerequisite for the subsequent analysis step, which was 
based on the observation of an inverse  linear correlation between velocity  and  
substrate  concentration  according  to  Lineweaver-Burk  equation  (Eq.2)  and 
Eadie-Hofstee linear regression (Eq.3) 
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                                                                    (Equation 3) 
 
where E0  is the total enzyme concentration, v is the actual rate (expressed as mol/s), 
Km  is the Michaelis-Menten equilibrium constant (expressed as mol), kcat is the rate-
limiting step kinetic constant (expressed as s-1), [S] is the substrate concentration 
and VMAX  the ratio between E0 and v. Linear  regression plots were constructed 
from the velocity data and the catalytic parameters kcat  and Km  were  extracted. 
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The pH dependence of the catalytic parameters has been fitted according to the 
following equations 
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where obskcat/Km, obskcat  and obsKm  are the observed parameter(s) as a function of 
pH, ikcat/Km, ikcat  and  iKm  are the parameter(s) for the ith-protonated form(s), 
iKua  are the ith  protonation constant(s) for the free enzyme E and iKLa are the ith 
protonation constant(s) for the substrate- bound enzyme ES when it is  involved in 
the cleavage event at the rate-limiting step. The global fitting procedure, employing 
simultaneously Eqs. (4a-4c) to describe the pH dependence of  all  three catalytic 
parameters of Zmp1 (i.e., kcat/Km, kcat  and Km), allows to determine the pKa of 
protonating groups, which modulate the enzymatic activity of Zmp1. 
Inhibition assay 
For inhibition experiments, Zmp1 (10 nM) was preincubated with EDTA, 
phosphoramidon and 1,10-phenanthroline (Sigma) in the universal buffer (see 
above) at RT before addition of the synthetic fluorogenic substrate. Fluorescence 
was measured after 5 min of incubation with the fluorogenic substrate (5 µM) at 
37°C. In the case of Ilomastat (British  Biotech Pharmaceutical, Cowley, Oxford, UK) 
the inhibition constant KI was measured obtaining the various Km from the 
substrate concentration dependence  at various inhibitor concentration, employing  
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Eqs (2) and (3) and then plotting data of Km as a function of inhibitor concentration, 
as from the following equation 
[ ] )1(0
I
mm K
IKK +⋅=                    (Equation 5) 
where Km is the Michaelis constant at different inhibitor concentrations, 0Km is the 
Michaelis constant in the absence of the inhibitor, [I] is the inhibitor concentration 
and KI is the inhibition constant. 
Peptide array 
Peptide Array was performed at JPT Berlin using a commercially available 
microarray (JPT Peptide  Technologies GmbH, Berlin, Germany; batch# 1562, both 
for peptidase incubation and control incubation in triplicates). The library consists 
of 1989 octameric peptides derived from annotated cleavage sites of peptidases or 
random sequences and 1536 pentadecameric random peptide sequences. Peptides 
contain a C-terminal phosphorylated tyrosine for detection with an anti-
phosphotyrosine antibody. The peptide microarray was incubated with 10 µg/ml 
Zmp1 (total reaction volume 400 µl) for 4 h at 37°C, using a microarray sandwich 
like construction. As a control sample an additional incubation was carried out in 
the absence of the target peptidase, which was followed by washing steps with 50 
mM TBS-buffer, pH 7.2 and ddH2O. Subsequent drying with a microarray 
centrifuge was performed. Microarrays were first incubated with anti-pTyr-antibody 
(for about 45 minutes) and then for 30 minutes with Dylight 649-labelled anti-
mouse-antibody. For detection, a Tecan HS4800 microarray processing station was 
employed. Total  incubation time was 45 minutes for anti-pTyr-100- antibody and 
30 minutes for anti-mouse-antibody,  followed  by washing steps with 50 mM TBS 
pH 7.2 and SSC buffer, pH 7.0 (JPT). Finally, the microarray plates were dried 
using a nitrogen stream. Analysis was performed with high resolution 
fluorescence scanner  (Axon Genepix 4200 AL Scanner) and Spot-recognition 
software Genepix 6.0 and Microsoft Excel was employed for data analysis. A 
reduction by more than 90% of signal intensity was considered as effective 
cleavage. 
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Cleavage site determination by MALDI-TOF 
Peptide cleavage assay was performed as following: 100 µM neuropeptides were 
incubated with or without Zmp1 (20 nM) for 5 min at 37°C in a total volume of 
200 µl. Then, 1 µl of a 1:100 dilution with MALDI Matrix solution (consisting of 
60% acetonitrile, 0.1% TFA in ddH2O and 4 mg/ml α-cyano-4-hydroxy cinnamic 
acid) was spotted the MALDI plate. After evaporation of solutes, MALDI spectra 
were recorded with a 4800 plus MALDI TOF/TOF Analyzer (Applied 
Biosystems, Foster City, CA). MALDI was equipped with a 355 nm Nd:YAG 
laser which operates at a repetition rate of 200 Hz. MS spectra were acquired in 
the reflectron mode, typically in the mass range from 600 to 4000 Da. The MS  
spectra were externally  calibrated  using  a  standard  peptide  mixture  (Applied  
Biosystems).  Recording software was 4000 Series Explorer and for the final 
preparation of the figures, Data Explorer, Microsoft Excel and Prism Graph were 
used. 
LC-MS of bradykinin sequence 
Bradykinin-elongated peptide with the sequence H2N-RPPGFSPFRSVTV-NH2  (C-
terminally tagged  with an amide group to avoid negative charge effects) was 
synthesized by JPT and dissolved in the assay buffer (100 mM Tris pH 7.3, 100 
mM NaCl, 10 mM CaCl2) at a final concentration of 1 mg/ml. Zmp1 was added to 
individual vials at concentrations of 10, 40 and 200 nM; a vial was kept in the 
absence of peptidase as a control. At different time intervals 8 µl were injected 
into LC-MS system and UV traces were recorded with Agilent LC-1200 VWD 
Detector at 220 nm; MS traces were recorded using Agilent Single-Quad G6130 
mass spectrometer. All evaluations were performed with Agilent chemstation 
B0301 data analysis software. 
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Supplementary data 
 
Table S1. List of protein subsequences efficiently cleaved by Zmp1 
Depicted is the ranking of particular cleavage sequences according to the cleavage 
rate. The name of the protein, the annotation, the specific sequence and the functional 
group are given. 
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Figure S1. Selwyn stability test on Zmp1 
RFU plotted as a function of the product of enzyme concentration and time. 50, 100, 
150 nM Zmp1 were incubated with synthetic substrate over a period of 200 s. The 
points lie close together within the limits of experimental error for different enzyme 
concentrations. 
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Figure S2. Cleavage sites of substance P by Zmp1 
Determination of fragments of substance P by Zmp1 through LC-MS analysis. (A) 
MALDI-TOF spectrum of fluorogenic substance P. (B) MALDI-TOF spectrum of 
Zmp1 hydrolyzed fluorogenic substance P. The arrows above the amino acid 
sequence of substance P indicate the cleavage sites. 
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Figure S3. Cleavage sites of angiotensin I by Zmp1 
Determination of fragments of angiotensin I by Zmp1 through LC-MS analysis. (A) 
MALDI-TOF spectrum of fluorogenic angiotensin I. (B) MALDI-TOF spectrum of 
Zmp1 hydrolyzed fluorogenic angiotensin I. The arrows above the amino acid 
sequence of angiotensin I indicate the cleavage sites 
 
 
 
 
 
 
 
 
 
 
 
 118
Figure S4. Cleavage sites of apelin-13 by Zmp1 
Determination of fragments of apelin-13 by Zmp1 through LC-MS analysis. (A) 
MALDI-TOF spectrum of fluorogenic apelin-13. (B) MALDI-TOF spectrum of Zmp1 
hydrolyzed apelin-13. The arrows above the amino acid sequence of apelin-13 
indicate the cleavage sites. 
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Figure S5. Cleavage sites of dynorphin A by Zmp1 
Determination of fragments of dynorphin A by Zmp1 through LC-MS analysis. (A) 
MALDI-TOF spectrum of fluorogenic dynorphin A. (B) MALDI-TOF spectrum of 
Zmp1 hydrolyzed fluorogenic dynorphin A. The arrows above the amino acid 
sequence of dynorphin A indicate the cleavage sites.  
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Figure S6. Cleavage sites of neurotensin by Zmp1 
Determination of fragments of neurotensin by Zmp1 through LC-MS analysis. (A) 
MALDI-TOF spectrum of fluorogenic neurotensin. (B) MALDI-TOF spectrum of 
Zmp1 hydrolyzed fluorogenic neurotensin. The arrows above the amino acid 
sequence of neurotensin indicate the cleavage sites.  
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PART II - Generation of three vaccine strains 
against tuberculosis 
 
Introduction 
The limited efficacy of BCG vaccine reflects the innate ability of mycobacteria to 
escape the host immune defence, especially the processing and presentation of 
antigens on the cell surface. The key for optimizing vaccination strategies against 
tuberculosis lies in improving access of mycobacterial antigens to presentation 
pathways and thus enabling high-quality T-cell priming. The genetic inactivation of 
BCG genes directly or indirecty involved in the suppression of antigen presentation 
is a promising approach for developing new vaccines, as shown by deleting the zinc 
metallopeptidase zmp1 (Johansen et al., 2011). The rationale of this approach is based 
on the hypothesis that the zinc metallopeptidase Zmp1, as player in the phagosome 
maturation arrest, affects the downstream antigen presentation process, particularly 
the MHCII-dependent pathway. Johansen and colleagues demonstrated that zmp1 
deletion increased the immunogenicity of BCG both in vitro and in vivo. Indeed, the 
authors showed an increased MHC class II-restricted antigen presentation in BCG 
∆zmp1 infected murine bone marrow-derived dendritic cells compared to the wild-
type. As consequence of the increased antigen presentation, the enhanced BCG 
immunogenicity was demonstrated in vivo. Following immunization with BCG 
∆zmp1, the delayed-type hypersensitivity reaction was obtained with 1/10 of the 
dose required for BCG wt, and the antigen-specific T-cell proliferation increased 
along with the cytokine secretion of splenocytes. Finally, it was proved in wild-type 
and SCID mice that the enhanced immunogenicity of the zmp1 mutant is not 
associated with increased persistency or heightened pathology. Altogether these 
findings indicate an interconnection between phagosome maturation and 
immunogenicity. Mainly, they provide solid evidences for further developing the 
vaccine candidate BCG ∆zmp1. The mutant was generated in the substrain Pasteur, 
and carries an integrated kanamycin resistance cassette (Master et al., 2008). 
The ability of M. tuberculosis to arrest the phagosome maturation confers the 
enormous advantage to live in a protected niche isolated from the cytosol, where the 
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MHCI-dependent antigen presentation occurs. By impairing its ability to reside in 
the phagosome, S. Kaufmann created a promising vaccine strain named VPM1002 
now manufactured by Vakzine Project Management GmbH. The scientific 
nomenclature for VPM1002 is recombinant M. bovis BCG ureC::hly (genetic 
background “Danish, subtype Prague”). The strain carries a hygromycin resistance 
marker, it is therefore resistant to this non-therapeutic antibiotic. Instead, it is 
sensitive to antibiotics commonly used in the treatment of mycobacterial infection, 
e.g. isoniazid, ethambutol and rifampicin. The recombinant BCG derives from two 
genetic modifications: the disruption of the urease C gene and the introduction of 
the lysteriolysin (Hly) gene from Listeria monocytogenes. The lack of Urease C 
contributes to maintain an acidic environment within the phagosome, essential for 
the activity of the pore-forming protein lysteriolysin. Mycobacterial antigens are 
therefore released in the cytosol, being accessible to MHCI presentation. The 
subsequent induction of CD8 T cells is the key for a strong and effective host 
immune response (Grode et al., 2005), as illustrated in Figure 1.  
 
                                    
 
Fig.1 Mechanism of BCG ureC::hly vaccine strain. The recombinant strain BCG ureC::hly secretes 
lysteriolysin which provokes leakage of BCG mycobacteria and antigens into the cytoplasm. 
Cathepsins released in the cytosol induce apoptosis. This results in potent MHCI presentation, 
enhanced apoptosis, increased cross-priming and uptake by dendritic cells. The overall response 
involves CD8 and CD4 T cells as well as γδ T cell and CD1-restricted T cells (Kaufmann et al., 2005). 
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The vaccine strain VPM1002 successfully completed preclinical studies, proving 
advanced safety profile in 10 studies comprising approximately 600 animals, from 
immune deficient mice to macaques (Grode et al., 2005). The protective efficacy was 
tested in mice vaccinated with VPM1002 or BCG and subsequentially intranasally 
challenged using Beijing/W clinical isolate of M. tuberculosis. VPM1002 
demonstrated improved protection against the challenge as compared to BCG 
(reduced CFU in the lungs by more than 100-fold at 200 days p.i.). Finally, toxicity 
studies performed in rodents (guinea pigs and neonatal rabbits) with high doses of 
VPM1002 have proved absence of adverse effect and normal weight development. 
The animal study findings supported the use of this vaccine in humans. VPM1002 
successfully completed two Phase I clinical trials. The Phase Ia and Ib clinical trials 
have evaluated safety, local and systemic tolerability and immunogenicity of 
VPM1002 in healthy adult caucasians and healthy adult africans compared to 
reference control (BCG), respectively. Currently, a Phase II open label, randomized, 
controlled study is ongoing in South Africa to evaluate safety and immunogenicity 
of VPM1002 in comparison with BCG in HIV-unexposed, BCG naïve newborn 
infants. The preclinical and clinical safety data confirm that a single vaccination with 
VPM1002 up to a dose of 5x10e5 CFU is safe and well tolerated. The vaccine has 
shown all the characteristics of safety, tolerability and efficacy needed to replace 
BCG immunization in the future (Vakzine Projekt Management GmbH_VPM1002).  
The BCG ∆zmp1 and VPM1002 are two promising vaccine candidates, though the 
second is in a much more advanced state (Fig.2). The encouraging results obtained 
in mouse model with BCG ∆zmp1 lead to further test the immunogenicity of the 
strain in other animal models with the perspective to enter in clinical trials. The 
future application of the vaccine strain in clinical trials requires the absence of 
resistance markers in the bacterial genome. Moreover, the M. bovis BCG substrain 
Denmark is nowadays accredited in the states of the European Union as official BCG 
vaccine.  
The aim of this work is to create vaccine candidates with appropriate characteristics 
for further application in humans. Thereby, here is described the generation of the 
strains BCG ∆zmp1 and BCG ureC::hly both unmarked, in the substrain Denmark. 
The combination of the properties of BCG ∆zmp1 and BCG ureC::hly might further 
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improve BCG with respect to protective efficacy by triggering both antigen 
presentation pathways, MHCI and MHCII simultaneously. Therefore, we generated 
the combinatorial vaccine strain BCG Denmark ∆zmp1 ureC::hly, sensitive towards 
all first and second line tuberculosis drugs. 
 
 
Fig.2 The current status of the vaccines BCG ∆zmp1 and VPM1002 in the pipeline of live TB vaccines. 
In the boxed inset is shown the MHCII-dependent antigen presentation upon phagocytosis of BCG 
antigens by macrophages (or dendridic cells). BCG RD1+ will most likely not further develop because 
of virulence over BCG (Kaufmann and Gengenbacher, 2012).  
 
Experimental procedures 
Bacterial strains and growth conditions 
Escherichia coli XL-1 blue MRF: ∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 supE 44 
thi-1 recA1 gyrA46 relA1 lac[F’proAB lacIqZ ∆ M15 Tn 10(Tetr)]C (Stratagene). E. coli 
was used for initial cloning. 
M. bovis BCG Denmark (1331) was obtained in the form of a vaccine production lot 
through the Statens Serum Institute, Copenhagen, Denmark.  
Bacterial growth conditions and conservation 
E. coli was grown in LB (Luria-Bertani) broth or on LB agar. M. bovis BCG Denmark 
was grown in Middlebrook 7H9 broth or on Middlebrook 7H10 agar, supplemented 
with 10 % oleic acid albumin, dextrose (OADC, Difco). The strain arrived in freeze-
dried (lyophilized) state and was reconstituted under laminar flow by dissolving the 
powder in 1 ml sterile saline (0.9 %). 10 µl of the solution were plated in 7H10 agar 
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plates and single colonies used for further applications. When appropriate, 
antibiotics were added to the media in the following concentrations: ampicillin 100 
µg/ml, hygromycin 100  µg/ml for E. coli or hygromycin 25 µg/ml, kanamycin 50 
µg/ml for M. Bovis BCG. E. coli was grown over night, M. bovis BCG for 3-4 weeks at 
37 °C in either a plate incubator or in static cultures. E. coli was frozen and stored at  
- 80 °C in LB medium containing 10 % (v/v) glycerol. M. bovis BCG was frozen and 
stored at -80 °C in a 0.9 M NaCl solution. The vaccine strains obtained in this work 
were titrated and stored at -80 °C in 7H9 medium. 
Preparation of electro-competent bacteria and transformation 
E. coli was used for initial cloning and propagation of plasmids. An overnight 
culture of E. coli strain XL-1 blue was inoculated in 1 L of LB medium and cultivated 
at 37 °C until OD600 0.5-0.6. To prepare electrocompetent bacteria, cells were 
harvested by centrifugation at 5000 g for 15 min at 4 °C and washed twice with an 
equal volume of ice-chilled 1 mM HEPES pH 7.0. The washing procedure was 
repeated twice with an equal volume of 10% glycerol. Finally, bacteria were 
resuspended in 5-10 ml of 10% glycerol. The suspension was divided in 40 µl 
aliquots, frozen in liquid nitrogen and stored at -80 °C until use. For electroporation, 
40 µl of competent bacteria were mixed with 2 µl of precipitated ligation reaction or 
0.1 µg of supercoiled plasmid DNA (transformation control) respectively and kept 
on ice for 5 min. Electroporation was performed in 0.1 cm cuvettes with a single 
pulse ( 1.8 kV, 2 µF, 200Ω, Gene Pulser XcellTM BioRad). After a recovery phase of 1 h, 
the bacteria were selected by plating 100 µl of electroporated bacteria on LB agar 
plates containing the appropriate antibiotic. Plates were incubated for 14-20 h at 37 
°C.  
M. bovis BCG Denmark was cultivated in 7H9 medium at 37 °C, and 20 ml pre-
culture was used for inoculation in 200 ml 7H9 medium. The culture was grown for 
25 days and one day before harvesting, BCG cells were induced with 20 ml 15% 
glycine. The following day cells were centrifuged at 5000 g for 20 min and 
resuspended in 10% glycerol. The washing and pooling was performed 4 times and 
finally cells were resuspended in 4 ml 10% glycerol. Aliquots of 400 µl were 
immediately used for electroporation. Each aliquot was mixed with 1 µg of 
supercoiled plasmid DNA and incubated for 5-10 min at RT. Electroporation was 
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performed in 2 mm cuvette with a single pulse (2.5 kV, 1000 Ω and 25 µF). After 
recovery phase of 24 h, the bacteria were selected by plating 2 ml of bacterial 
suspension on 7H10 agar plates containing the appropriate antibiotic. Plates were 
incubated for 3-4 weeks at 37 °C. Single colonies were picked, amplified and 
analyzed by PCR or Southern blotting for detection of positive clones. 
Isolation of mycobacterial genomic DNA 
M. bovis BCG was grown on half a plate of Middlebrook 7H10 with appropriate 
antibiotics. The bacteria were scraped and resuspended in 350 µL TE buffer. After a 
20 min heat inactivation step at 80 °C, the bacteria solution cooled down to RT. 2 µl 
20 % (v/v) Tween 80 and 10 µL lysozyme (80 mg/ml) were added to the samples, 
followed by an incubation step for 2 hours at 37 °C / 1000 rpm. In a second incuba-
tion step 40 µL 10 % SDS and 20 µL proteinase K (1 mg/ml) were added to the 
samples and incubated at 50 °C for 1 hour. For DNA extraction, 400 µl of 
phenol/chlorophorm/isoamylalcohol (25:24:1) was added, mixed by hand and then 
centrifuged at 16000 g for 20 min at 4 °C. The aqueous phase was transferred into an 
Eppendorf tube and the DNA precipitated by adding 8 µL of 5 M NaCl and 1 mL of 
ethanol. After centrifugation at 16000 g for 20 min at 4 °C, the supernatant was 
discarded and the pellet washed with 70 % ethanol. After drying under vacuum the 
DNA was resuspended in 50-100 µL of TE buffer. 
Southern Blotting 
2 µg of genomic DNA was digested with an appropriate restriction enzyme. The 
resulting fragments were then separated by agarose gel electrophoresis according to 
standard protocols. DNA was transferred to a positively charged nylon membrane 
(Roche) by vacuum blotting using a VacuBlot System (Biometra). Subsequently, the 
DNA was cross-linked to the nylon membrane by UV-irradiation using an UV-
Stratalinker (Stratagene). A digoxigenin (DIG)-labelled probe was hybridized to the 
DNA, washed under stringent conditions, and detected by an anti-DIG antibody 
coupled to a horseradish peroxidase (Roche). The DNA probe was generated by 
PCR amplification of a 200-1000 bp DNA fragment, which was labelled with 
digoxigenin (DIG) according to the manufacturer’s protocol. 
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Targeted gene deletion in mycobacteria 
Allelic replacement technique was used to generate isogenic gene knock-outs in M. 
bovis BCG Denmark. The two suicide vectors pGEM7_sacB_hyg_aph and 
pMCS5_sacB_hyg, which cannot replicate in mycobacteria, were used. These vectors 
contain the selectable hygromycin and/or kanamycin resistance markers and sacB, a 
counterselectable marker, which kills slow-growing mycobacteria at 10% sucrose 
concentration in the culture medium (Pelicic et al., 1996). To generate an unmarked 
gene deletion in M. bovis BCG, 1000 to 1500 bp flanking regions of the target gene 
were amplified, fused together and ligated into the suicide vector. The vector was 
transformed in BCG and selected on Middlebrook 7H10+Hyg. Bacteria that 
integrated the vector through homologous recombination (single cross-over event) 
became resistant to hygromycin and grew on the agar plates. The cross-over 
transformants were confirmed by PCR and Southern blot analysis. Single cross-over 
transformants were subjected to counterselection step. Thereby a bacterial 
suspension was plated on Middlebrook 7H10 supplemented of 10% sucrose. Under 
the sucrose pressure, only bacteria that have lost the sacB-containing vector through 
a second cross-over event will survive (Fig.3). Resulting clones were analyzed by 
PCR and Southern blot for allelic replacement of the targeted gene or reversion to 
the wild-type, respectively.     
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Fig.3 Schematic representation of allelic exchange via suicide counterselectable plasmid. The first 
event is the single homologous recombination between zmp1 gene (as example) on the chromosome 
and the deleted allele present on the plasmid. This event results in the generation of a single cross-
over strain. The second step involves the subsequent intrachromosomal recombination event between 
the wild-type zmp1 allele and the deleted allele of zmp1. When the site of recombination is a, then the 
vector sequences are lost and the wild-type allele is left in the chromosome. When the site of 
recombination is b, the deleted allele remains in the chromosome and the wild-type and the vector 
sequences are lost  (Clark, 2002). 
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Table 1. Primers used in this study. 
a: forward primer; b: reverse primer; colored letters indicate recognition sites for restriction 
endonuclease enzymes 
No. sequence function 
1a 
CTA GCT GAC TGA CTG AGG ATC 
CCG 
triple translation stop insert NheI overhanged. 
Internal BamHI site 
2b 
CTA GCG GGA TCC TCA GTC AGT 
CAG  
triple translation stop insert NheI overhanged. 
Internal BamHI site 
3a GTT GAC GGT TTG TGG TGT CAT sequencing zmp1-stopcodons 
4b TCG ACC CGT TAC TTG GTG CA sequencing zmp1-stopcodons 
5a ATG CCT GAC GGG GAG CAG amplification of DNA probe for BCG ∆zmp1 
6b GGA GAT CAT CAG CTT GCC G amplification of DNA probe for BCG ∆zmp1 
7a 
AGA CAA TTG GAA CAC CGC CTC 
GTC ACC 
amplification of ureC upstream region. MunI 
linked 
8b 
CCG CAA TTG CCA GAG CTC CCT 
GCT CGA AAC CGT TGA AC 
amplification of ureC upstream region. MunI 
and Ecl136II linked 
9a 
GGT GAG CTC GTC GGT GAA GGT 
GTC GGG A 
amplification of ureC downstream region.  
Ecl136II linked 
10b 
CCG CAA TTG AAC AGC ACT GTT 
TTT ATG TGT GTG A 
amplification of ureC downstream region. MunI 
linked 
11a CAC CTT CCA GTG CCC CG amplification of DNA probe for BCG ureC::hly  
12b CGA ATG TAC TGC CCA GCT C amplification of DNA probe for BCG ureC::hly  
 
 
Table 2. Plasmids used and generated in this study 
plasmid characteristics source 
pGEM®-T easy For safekeeping of PCR products, AmpR Promega 
pGEM7_sacB_hyg_aph  
Suicide vector for homologous recombination. HygR, 
KanR. SacB as counterselectable marker. 
(Keller et al., 
2008) 
pMCS5_sacB_hyg 
Suicide vector for homologous recombination. HygR. 
SacB as counterselectable marker. 
(unpublished 
data) 
pMV361_hyg 
E. coli – mycobacteria shuttle vector, integrative in 
mycobacteria attP, int. KanR, HygR. Used in this study 
as positive control for mycobacteria transformation 
(Stover et al., 
1991) 
ptrpA1_rpsL_zmp  
Suicide vector for homologous recombination. RpsL as 
counterselectable marker. It carries 4423 bp of the 
zmp1 locus. Used as cloning intermediate. 
(Master et al., 
2008) 
ptrpA_rpsL_zmp3XSTOP 
Derivate of ptrpA1-rpsL-zmp1, it carries the 3 stop 
codons insert within zmp1 gene.  
This study 
pzmp_sacB_aph_hyg  
Derivate of pGEM7_sacB_hyg_aph, it carries the 
disrupted zmp1 gene and its flanking regions (3670 
bp).  
This study 
pureC::hyg_Hly  
Cosmid vector derived by pYUB854. It carries the ureC 
locus disrupted by hyg resistance marker and hsp60-
Ag85-hly gene. 
S. Kaufmann 
pureC::Hly_sacB_hyg 
Derivate of pMCS5_sacB_hyg, it carries the ureC locus 
disrupted by hsp60-Ag85-hly gene. 
This study 
 
 130
Results 
Generation of the vaccine strain BCG Denmark ∆zmp1 (unmarked) 
Deletion of zmp1 gene was performed by using the plasmid ptrpA1_rpsL_zmp 
(Master et al., 2008). The plasmid carries the M. tuberculosis zinc metallopeptidase 
zmp1 (Rv0198c; open reading frame: start 236’507; stop 234’519; 1992 bp; 
http://tuberculist.epfl.ch/) and its flanking regions, for a resulting fragment of 4423 
bp (Fig.4). The cloning strategy is represented in Figure 5. Two adjacent NheI 
fragments within the zmp1 open reading frame, comprising a total of 776 bp, were 
replaced by a 24-mer triple translation stop insert with an internal BamHI restriction 
site and NheI overhanging ends (Fig. 6). The 24-mer fragment was generated by 
annealing of oligonucleotide primers with 5’-phosphorylated ends (primer pairs: 1a 
and 2b). The oligonucleotides were diluted in annealing buffer (10 mM Tris-HCl, pH 
8.0; 50 mM NaCl; 1mM EDTA) to a concentration 10 µM. The two oligonucleotides 
were mixed at equal volumes, resulting in a final concentration of 5 µM per 
oligonucleotide. The mixture was heated to 96° C for 5 minutes in a PCR machine 
and cooled down to 25° C for 8 hours. The annealing product was diluted 1:10 and 
used for ligation. The final product is the plasmid ptrpA_rpsL_zmp3XSTOP. The 
sequencing of the inserted region has confirmed the presence of the 3 stop codons. 
The plasmid ptrpA_rpsL_zmp3XSTOP was digested with NotI and the disrupted 
zmp1 gene including its flanking regions (3670 bp) was cloned into NotI-linearized 
suicide vector pGEM7_sacB_aph_hyg. The resulting suicide plasmid 
pzmp_sacB_aph_hyg was transformed into M. bovis BCG Denmark, leading to 
generation of the knock-out strain named BCG ∆zmp1. The gene knock-out was 
confirmed by Southern blot using a 639 bp PCR fragment (primer pair: 5a and 6b) as 
probe (Fig.7).  
The sensitivity of the strain against hygromycin, kanamycin, streptomycin and 
rifampicin was proved by streaking the strain on plates containing these antibiotics. 
The strain was then titrated and stored at -80° C for further vaccination studies in 
animal models.  
 
 
 131
 
Fig. 4 A. Zmp1 locus in M. tuberculosis. The blue box represents the region cloned in the vector 
ptrpA1_rpsL_zmp. The M. tuberculosis zmp1 locus is equivalent in M. bovis BCG. Rv0197 has 99.9% 
identity with Mb0203, but 100% identity on amino acid level. B. Vector map of ptrpA1_rpsL_zmp. 
 
 
 
 
Fig.5 Cloning of the suicide vector pzmp_sacB_aph_hyg for generation of mycobacteria unmarked 
knock-out of zmp1 gene. 
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Fig.6 24-bp triple translation stop insert with BamHI restriction site and NheI overhanging ends. The 
synthetic insert contains a stop codon for every reading frame. 
 
 
 
Fig. 7 Southern blot analysis confirming the deletion of zmp1 from the genome of M. bovis BCG 
Denmark. A. Schematic drawing of the wild-type BCG zmp1 locus. The blue box corresponds to the 
region which was deleted in the knock-out strain. The magenta box indicates the probe, located 
upstream to zmp1 gene. The restriction endonucleases HindIII and EcoRV were used in combination 
to digest the genomic DNA of M. bovis BCG Denmark. B. The wild-type band (WT) was calculated to 
be 3704 bp long. The 3’ single cross-over (sco) fragments correspond to lengths of 3836 bp and 2950 
bp respectively. The knock-out strain (KO) fragment corresponds to a length of 2950 bp. 
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Generation of the vaccine strain BCG Denmark ureC::hly (unmarked) 
The vaccine strain VPM1002 was generated by transformation of the plasmid 
pureC::hyg_Hly in the BCG substrain Prague. This plasmid was used in this study 
for the generation of the unmarked vaccine strain in the substrain Denmark. The 
vector carries two regions named ureC P1 and ureC P2. The first region includes 658 
bp upstream of the gene ureC (Rv1850; open reading frame: start 209’796; stop 
211’530; 1734 bp; http://tuberculist.epfl.ch/) and 147 bp of the gene ureC, while the 
second region comprises 840 bp of the gene ureC (Fig.8). The ureC gene is disrupted 
by insertion of the hygromycin resistance marker and the gene hly coding the 
listeriolysin from Listeria monocytogenes fused to Antigen 85B signal peptide (for 
secretion of listeriolysin) and under transcriptional control of hsp60 mycobacterial 
promoter.  
 
Fig. 8 A. UreC locus in M. tuberculosis. The blue boxes represent the regions ureC P1 and ureC P2 in 
the vector pureC::hyg_Hly. M. tuberculosis ureC locus is equivalent in M. bovis BCG. B. Vector map of 
pureC::hyg_Hly. 
 
The cloning strategy is described in Fig. 9. The ureC P1 region (named upstream) 
was subcloned into pGEM-T easy by insertion of the amplified region (primer pairs 
7a, MunI linked and 8b, MunI and Ecl136II linked), resulting in the vector 
UP_pGEMTeasy. The ureC P2 region along with hsp60-Ag85-hly gene (named 
downstream) was subcloned into pGEM-T easy by insertion of 3185 bp PCR product 
externally linked with Ecl136II and MunI restriction endonuclease sites (primer pairs 
9a and 10b). The product is the vector DOWN_pGEMTeasy. The upstream region 
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was excised by MunI digestion and subsequentially ligated into the MunI-linearized 
DOWN_pGEMTeasy vector, generating UP+DOWN_pGEMTeasy. The fused 
upstream and downstream region (total length 3990 bp) was excised by Ecl136II 
digestion and blunt ligation was performed into EcoRV-linearized 
pMCS5_hyg_sacB. The final vector, pureC::Hly_sacB_hyg, was transformed into M. 
bovis BCG Denmark, leading to generation of BCG ureC::hly. The gene knock-out 
along with the insertion of the hly gene was confirmed by Southern blot using a 300 
bp PCR fragment (primer pair: 11a and 12b) as probe (Fig.10). 
The sensitivity of the strain against hygromycin, kanamycin, streptomycin and 
rifampicin was proved by streaking the strain on plates containing these antibiotics. 
The strain was then titrated and stored at -80° C for further vaccination studies in 
animal models.  
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Fig.9 Cloning strategy for generation of the suicide plasmid pureC::Hly_sacB_hyg.  
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Fig. 10 Southern blot analysis confirming the deletion of ureC from the genome of M. bovis BCG 
Denmark and the insertion of  Ag85-hly gene. A. Schematic drawing of the ureC gene in the wild-type 
strain (left) and of the disrupted ureC gene with inserted Ag85-hly gene in the knock-out strain (right). 
The blue boxes represent the ureC P1 and P2 regions used for homologous recombination. The 
magenta box indicates the probe, located in the ureC P2 region. The restriction endonuclease NheI 
was used to digest the genomic DNA of M. bovis BCG Denmark. B. The wild-type band (WT) was 
calculated to be 5546 bp long. The 5’ single cross-over (sco) fragments correspond to lengths of 2735 
bp and 10842 bp respectively. The knock-out strain (KO) fragment corresponds to a length of 4741 bp.  
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Generation of the vaccine strain BCG Denmark ∆zmp1 ureC::hly (unmarked) 
In order to combine the genetic characteristics of the two newly generated vaccine 
strains, the plasmid pureC::Hly_sacB_hyg (used for generating the strain BCG 
ureC::hly) was transformed into BCG ∆zmp1. Finally, the strain generated was 
named BCG ∆zmp1 ureC::hly. The confirmation of the genetic recombination was 
assessed by Southern blot applying the strategy previously used to confirm BCG 
ureC::hly (Fig.11). The strain has peculiar genetic characteristics: deletion of zmp1 and 
ureC genes, insertion of hly gene and absence of antibiotic markers in the genome.  
The sensitivity of the strain against hygromycin, kanamycin, streptomycin and 
rifampicin was proved by streaking the strain on plates containing such antibiotics. 
The strain was then titrated and stored at -80° C for further vaccination studies in 
animal models.     
                                
 
Fig. 11 Southern blot analysis confirming the deletion of ureC from the genome of BCG ∆zmp1 along 
with the insertion of  Ag85-hly gene. Although the background strain is BCG ∆zmp1, the first lane is 
named WT referring to ureC locus. The strategy used was described above for the confirmation of 
BCG ureC::hly.  
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Discussion 
In the past years, it became clear in the scientific world that most of the efforts 
dedicated to fight tuberculosis should have been addressed in development of 
effective vaccines. One of the most successful vaccine candidate currently involved 
in clinical trials is VPM1002; its advanced safety and protection profiles drove it 
straight forward to Phase II trials. The strategy used to generate it proves that the 
escape of mycobacterial antigens in the host cytosol is a successful trick to enhance 
the effectiveness of vaccine. Solid evidences supporting this concept are provided by 
the recent work of Brosch and colleagues (Simeone et al., 2012). Their fluorescence 
microscopy-based approach elegantly proves the translocation of M. tuberculosis in 
the host cytosol from 3 days post infection. This event was correlated to the presence 
of the RD1 region, and precisely to ESAT-6 which is hypothesized to have pore-
forming activity. Most interestingly, BCG vaccine strain, lacking RD1 region, 
remains in the phagosome and by complementation with the RD1 region, it gains 
access to the host cytosol. The RD1-dependent phagosomal escape is the 
determinant of a substantially different immune response against M. tuberculosis and 
BCG. In fact, Mtb is able to induce strong CD4 T cell activation and several 
important cytosolic recognition pathways, such as CD8 T cells and type I interferon 
responses along with NLRP3 inflammasome activation (Simeone et al., 2012). In 
contrast, BCG is an ineffectual inducer of CD8 T cells although it is still capable of 
stimulating CD4 T cell response (Kaufmann, 2004). It is clear from this study that a 
more effective vaccine strain should have the capacity to access to the cytosol in 
order to trigger the immune responses naturally elicited by Mtb. As unable to 
induce Mtb-like immune responses, the currently available BCG vaccine is 
uneffective.  
The great potential of a strategy based on phagosomal escape was caught by S. 
Kaufmann, leading to the generation of a recombinant BCG provided with the pore-
forming listeriolysin. The progression of the vaccine strain through clinical trials 
made of primary importance to generate a recombinant BCG ureC::hly having the 
characteristics needed for a future distribution in the human population. Therefore, 
this study provides the strain BCG Denmark ureC::hly, free of all antibiotic markers. 
The strain, generated by allelic replacement technique, was confirmed to carry the 
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deletion of ureC gene along with insertion of the hly gene. Although the expression 
of  listeriolysin in the strain VPM1002 was demonstrated, as well as the leakage of 
mycobacterial antigens in the cytosol of infected macrophages (Grode et al., 2005), 
these basic proofs have to be provided also for the newly generated strain. 
Furthermore, BCG Denmark ureC::hly (unmarked) has to be tested in animal models 
to prove the same or even better vaccine protection compared to VPM1002. 
Another promising strategy for developing effective vaccines against TB is based on 
the zinc metallopeptidase Zmp1. Zmp1 is an important player in pathogenicity as 
involved in the key process of phagosome maturation arrest promoted by Mtb. 
Zmp1-dependent phagosome maturation arrest is conserved in BCG. Zmp1 was 
therefore considered a target for vaccine development. The hypothesis that the lack 
of the peptidase could improve the immunogenicity by enhancing the MHCII 
dependent-antigen presentation was validated by Joahnsen and colleagues 
(Johansen et al., 2011).  The strain BCG ∆zmp1 was suggested as a potential vaccine 
candidate based on the protection and safety profile obtained in mouse model. The 
construction of the strain BCG Denmark ∆zmp1 (unmarked) was performed in this 
study in order to replace BCG Pasteur ∆zmp1 (marked) currently tested in guinea 
pigs model. The use of strains accomplishing the european requirements already in 
preclinical trial will accelerate future testing and will save costs and resources.  
The combination of the two vaccine strains generated in this study resulted in the 
recombinant BCG Denmark which carries the integration of the listeriolysin gene 
(hly) and is devoid of Zmp1 and Urease C. These genetic modifications acting in 
combination are supposed to improve MHCI as well as MHCII dependent-antigen 
presentation, enhance apoptosis and cross-priming, potentially triggering a more 
potent immune response than the single modifications. It is reasonable to assume 
that the combined strain BCG Denmark ∆zmp1 ureC::hly (unmarked) will have 
improved protection and safety profiles, and therefore will be more successful than 
each of the single gene mutants. 
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